**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Form 10-KSB

(Mark One)

X__Annual report under section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal
year ended December 31, 2000.

___Transition report under section 13 or 15(d) of the Securities Exchange Act of 1934 for the
transition period from ______ to ______.

**T.Z.F.  INTERNATIONAL INVESTMENTS, INC.******

(Exact name of registrant as specified in its charter)

|Nevada                                         | 0-31353                  | 88-0404186                          
|---------------------------------------------- | ------------------------ | ------------------------------------
|(State or other jurisdiction of
incorporation) | (Commission File
Number) | (IRS Employer Identification
Number)

|Unit 1, 3071 No. 5 Road

Richmond, B.C., Canada | V6X 2T4   
|----------------------------------------------- | ----------
|(Address of principal executive offices)        | (Zip Code)

Registrant's telephone number, including area code:  (604) 718-2188

Securities to be registered under Section 12(b) of the Act:





Securities to be registered under Section 12(g) of the Act:





Check whether the issuer (1) filed all reports required to be filed by  Section 13 or 15(d) of the
Securities Exchange Act during the past 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing requirements for the
past 90 days. Yes  X   No ____

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B
contained in this form, and no disclosure will be contained, to the best of registrant's knowledge,
in definitive proxy or information statements incorporated by reference in Part III of this Form
10-KSB or any amendment to this Form 10-KSB.___

State issuer's revenue for its most recent fiscal year: $1,868,276

State the aggregate market value of the voting stock held by non-affiliates computed by reference
to the price at which the stock was sold, or the average bid and asked priced of such stock, as of a
specified date within the past 60 days (See definition of affiliate in Rule 12b-2): -0-

Note: If determining whether a person is an affiliate will involve an unreasonable effort and
expense, the issuer may calculate the aggregate market value of the common equity held by
non-affiliates on the basis of reasonable assumptions, if the assumptions are stated.

(Issuers involved in bankruptcy proceedings during the past five years):

Check whether the issuer has filed all documents and reports required to be filed by Section 12,
13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a
court. Yes ____ No ____

(Applicable only to corporate registrants) State the number of shares outstanding of each of the
issuer's classes of common equity, as of the latest practicable date:35,897,309as of December
31, 2000.

(Documents incorporated by reference. If the following documents are incorporated by reference,
briefly describe them and identify the part of the Form 10-KSB (e.g. Part I, Part II, etc.) into
which the document is incorporated: (1) any annual report to security holders; (2) any proxy or
information statement; and (3) any prospectus filed pursuant to Rule 424(b) or (c) of the
Securities Act of 1933 ("Securities Act").  The listed documents should be clearly described for
identification purposes.

PART I

ITEM 1.   DESCRIPTION OF BUSINESS.

**Background**

The Company was incorporated under the laws of Nevada on September 14, 1998, as
Sabai Sabai Enterprises, Corp, and on May 25, 2000, changed its name to T.Z.F. International
Investments, Inc.  As a result of various acquisitions completed during the fiscal year ending
December 31, 2000, the Company has expanded rapidly.  It now owns several subsidiaries and
business operations in Canada and in China through which it manufactures, markets and
distributes pharmaceutical and health food products.   The Company's goal, through the
operations of its subsidiaries, is to become a market leader in distributing domestic and imported
health foods and medicines throughout China and in exporting Chinese health food products to
North America and elsewhere.

**Subsidiaries and Their Operations**

The Company has six directly and indirectly-owned subsidiaries in China and Canada
(including one subsidiary which will be indirectly owned, as to which the acquisition is still in
process), through which it undertakes research and development and through which it
manufactures, markets and distributes pharmaceutical and health food products.  All of these
acquisitions were completed during the fiscal year ending December 31, 2000.   The acquisition
of T.Z.F. International Herbs Investment, Inc., was completed in April, 2000.  As a result, its
operations were under the control of the Company for a significant portion of the year.  However,
the acquisitions of Tian'an Pharmacy (Xiamen) Co, Ltd., T.Z.F. International Herbs (Jiangsu)
Co, Ltd. (formerly Second Factory Pharmacy ofYangheng City), and Shenzhen Tianzifu Network
Technology Ltd.(and through it, the acquisition ofGuangdong Hongkang Pharmaceutical
Company)  were not completed until December, 2000.  Therefore, although the consolidated
financial statements included in this report include amounts for all of these subsidiary entities,
during the fiscal year ending December 31, 2000, the Company was not involved in management
of the operations of any of the subsidiaries which were acquired in December, 2000.

During the fiscal year ending December 31, 2001, the Company expects to work on
integrating and consolidating the operations of its various subsidiaries.  It is currently
contemplated that the Company's business operations will be organized as follows:

**China Headquarters -** Shenzhen Tianzifu Network Technology, Ltd.

**Sales Center, Northern China -**Shanxi Medicine Materials Supply and Marketing
Company (acquisition is in process)

**Sales Center, Southern China -**Guangdong Hongkang Medical Company

**Sales Center, North America -**T.Z.F. International Herbs Investment, Inc.

**Western Medicine Production Base -**T.Z.F. International Herbs (Jiangsu) Co., Ltd.

**Chinese Medicine Production Base -**Tian'an Pharmacy (Xiamen) Co., Ltd.

Additional information regarding each of the subsidiary companies follows:

TZF International Herbs Investment, Inc.

T.Z.F. International Herbs Investment, Inc. ("TZF Herbs") is a wholly-owned subsidiary
of the Company which was incorporated in 1998 under the laws of British Columbia, Canada.   It
is the Company's intent for TZF Herbs to serve as its North American sales center.



Through TZF Herbs, the Company owns the formula, distribution and intellectual
property rights, including trademark, patent and industrial design rights, for the "Snow Lotus
Tea" series products.  TZF Herbs acquired those rights from Shenzhen Hungyunda Enterprises
Co. Ltd. of China pursuant to an Assignment Agreement dated December 15, 1999. Prior to the
execution of the Assignment Agreement, TZF Herbs was licensed to develop, market, and
distribute the "Snow Lotus Tea" products in North America, but did not own the formula rights.

Snow Lotus Tea is primarily an extract of the snow lotus flower which grows in high
elevations in the mountains of Tibet and neighboring Chinese provinces.  It is marketed as a
treatment for rheumatic and rheumatoid arthritis.

In, October, 1998, the Canadian Food Inspection Agency approved the sale of Snow
Lotus Tea in Canada as a food product, and the Company is currently focusing its efforts on
selling the product in two markets in Canada.  One is the health food and supplements market, in
which the product is being marketed as a health food supplement.  The other market consists of
local Traditional Chinese Medicine practitioners, Naturopathic clinics and the Chinese
community throughout Canada, in which the product is considered to be a Chinese formula
natural remedy for arthritis.

In the future, the Company may apply to the U.S. Food and Drug Administration for
permission to sell Snow Lotus Tea as a food product in the U.S.  It is not known when, or
whether, the Company is likely to receive permission from the FDA to sell its product in the
United States.  In the future, the Company may also elect to seek approval from appropriate
governmental agencies in both Canada and the U.S. to market Snow Lotus Tea as an over-the-counter  medicine for the treatment of the symptoms of arthritis.  However, the process of
obtaining approval for sale of any product as an over-the-counter medicine is extremely time-consuming and expensive.  As a result, the Company may never have the funds or other
resources required to initiate that process.

The Company has filed trademark applications in the United States and Canada for the
tradename "Snow Lotus."

At the present time, Beijing Zhong Jia Yi Pharmaceutical Technology Development
Company produces Snow Lotus Tea under license from TZF Herbs and ships the product to
Canada for sale.  Since the Company has now acquired both Tian'an Pharmacy and Second
Pharmacy Factory, it is anticipated that production of Snow Lotus Tea will be transferred to these
facilities, thereby reducing manufacturing costs.

TZF Herbs is currently working on development of a North American sales and
distribution network for Snow Lotus Tea.  In the future, the Company expects to use this same
sales and distribution network to distribute and sell other Chinese health food products into
North America.  In addition, TZF Herbs has entered into an agent agreement with a Canadian
health foods producer and distributor, Trophic Health Foods Co., under which TZF Herbs will
become an exclusive agent for distribution of that company's products in China.

Shenzhen Tianzifu Network Technology Ltd.

On December 31, 2000, the Company completed the purchase of all of the assets of
Shenzhen Tianzifu Network Technology Ltd, ("Shenzhen Tianzifu"), a Chinese corporation.  The
assets acquired included Guangdong Hongkang Pharmaceutical Company which was a subsidiary
of Shenzhen Tianzifu.

The registered address of Shenzhen Tianzifu is 8 south Road, Dong Men, LouHu District,
Shenzhen City, GoangDong Province.  It will serve as the Company's China headquarters.  Iit owns
one subsidiary, Guangdong Hongkang Pharmaceutical Company, directly, and has an agreement to
acquire Shanzi Medicine.  The Company plans to control the operations of all of its current and
future subsidiaries in China through Shenzhen Tianzifu.



Currently, Shenzhen Tianzifu operates a Chinese-language health food Web site in China.
Its objective, though, is to centralize the management of the entire T.Z.F. network in China and to
improve its efficiency and economic scale, including that of the manufacturing, sales and marketing
functions. It will seek to further expand the existing distribution network and channels of all current
subsidiaries in China and will seek to carry out the T.Z.F.'s plan of building 200 chain counters and
stores in the top 200 department stores national wide, 50 licensed drug stores, 60 chain stores and
20 distribution centers in selected locations in China. Furthermore, once Shenzhen Tianzifu has
completed building the sales network platform domestically, it will then focus on attracting
international suppliers of health food or related health care products that wish to export their
products to China. It will then use this expanding international network to market Chinese health
food products and herbal medicines.

Shenzhen Tianzifu will apply the computer, network and database technology that it has
developed and is currently using in-house to consolidate, standardize and specialize its management
and distribution systems in order to maximize operating efficiencies. It will seek to implement a
Retailer Management System, an Electronic Ordering System and an Electronic Data Interchange
through which it will control the organization of the chain stores.  Its online network will be able to
present a virtual sales platform for the eventual B2B and B2C transaction.  In all, Shenzhen Tianzifu
will have seven departments: marketing, merchandise, sales, information center, distribution center,
general management/administration and accounting.

Guangdong Hongkang Pharmaceutical Company

Guangdong Hongkang Pharmaceutical Company is the subsidiary of Shenzhen Tianzifu. It
is anticipated that Guangdong Hongkang will serve as the Company's sales center in southern China.
It was formed in 1995 and is located in Meixian County in Guangdong Province. Hongkang
Pharmaceutical wholesales and retails chemical pharmaceutical preparations, antibiotic
pharmaceutical preparations, Chinese traditional medicine preparations and tablets and other health
products throughout Southern China including Guanxi, Fujian and Hunan provinces. The Company
plans to seek to expand the facilities and market share of Hongkang Pharmaceutical in order to meet
the growing demand for medicines and to become a major pharmaceutical distributor and wholesaler
in Southern China.

Shanxi Medicine Materials Supply and Marketing Company

Shenzhen Tianzifu has an agreement to acquire Shanxi Medicine Materials Supply and
Marketing Company.  As of the date of this report this acquisition was still in process.  It is
anticipated that Shanxi Medicine will serve as the Company's sales center in northern China.  Shanxi
Medicine was formed in 1988 and is currently a wholesale and retail distributor for Western and
Chinese medicines, raw materials and equipment for manufacture of medicines, and medical and
health facilities and equipment.  It is also engaged in research and development activities.   Through
Shenzhen Tianzifu, the Company intends to complete the acquisition of Shanxi Medicine during
calendar year 2001.

T.Z.F. International Herbs (Jiangsu) Co., Ltd.

On December 31, 2000, the Company completed the purchase of all of the assets of Second
Pharmacy Factory of Yancheng City, ("Second Pharmacy"), a Chinese corporation.  The assets were
purchased from The People's Government of JianWu County, JiangSu Province, the People's
Republic of China.   The Company has changed the name of this subsidiary to T.Z.F. International
Herbs (Jiangsu) Co, Ltd. ("T.Z.F. Jiangsu").  It is the Company's intent that T.Z.F. Jiangsu will serve
as it's base of operation for manufacturing medicines which meet North American product standards.

The cash purchase price for the assets of Second Pharmacy was paid on our behalf by Xin
Chen, one of our principal shareholders.  These payments were part of a total of $5,000,000 US
which Mr. Chen paid or advanced on our behalf during the fiscal year ending December 31, 2000.
The funds advanced by Mr. Chen were used for a variety of purposes including being used  in part
for purchase of the assets of Second Pharmacy and in part for purchase of all of the issued and
outstanding stock Tian'an Investments Limited, a British Virgin Islands Corporation (which was
completed on or about December 21, 2000 and described in a report on Form 8K dated December
21, 2000).  The  advances made on our behalf by Mr. Chen were initially treated as a loan.  However,
on December 31, 2000, Mr. Chen agreed to convert his loan to an equity investment, and our Board
of Directors authorized the issuance of shares of common stock and warrants to Mr. Chen in full
satisfaction of this loan.  (See ITEM 5. Other Events).

T.Z.F. Jiangsu (formerly known as Second Pharmacy Factory of Yancheng City)  is a medical
manufacturing plant located in Jiangsu Province. It was founded in 1971.   The factory produces both
pharmaceutical active ingredients and pharmaceutical preparations including chemically combined
pharmaceutical active ingredients, tablets, capsules, syrups, infusion solutions and tincture solutions.
Currently, it produces over 100 products, and is capable of manufacturing North American standard
products.

The factory currently operated by T.Z.F. Jiangsu includes an advanced production line, an
infusion production line with a capacity of 9 million bottles per year, and a capsule production line
capable of producing 5 million capsules per year.  It maintains a consistent program of advanced
research and development, and its assay center has various testing capabilities and a sound quality
assurance system.  It also has four sales departments and four branch offices and sells its products
throughout China.

It is the Company's intent to use the facilities and employees of T.Z.F. Jiangsu to continue
to produce its current product line and to expand its production to include additional health products.
The Company also intends to seek to expand the research and development operations conducted
at the T.Z.F. Jiangsu facility and to seek to increase the sales volume for the products which are
manufactured at its facility by expanding the sales team and linking it with the Company's  existing
marketing platform.

Tian'an Pharmacy (Xiamen) Co., Ltd.

On December 21, 2000, the Company acquired all of the issued and outstanding capital stock
of Tian'an Investments Limited, a British Virgin Islands corporation.  The sole asset of Tian'an
Investments Limited is its 100% ownership of Tian'an Pharmacy (Xiamen) Co.,  Ltd. ("Tian'an
Pharmacy"), a manufacturer of Chinese biological and herbal medicine products.   Tian'an Pharmacy
has a plant which is located in the Torch High Tech Development Zone of Xiamen, China, where
it currently conducts research and development and produces herbal and biological medicines which
its distributes and sells in China.Although Tian'an Pharmacy is capable of producing products
which satisfy North American standards, it is the Company's intent that Tian'an Pharmacy  will
serve primarily as its base of operation for manufacturing Chinese medicines.

Tian'an Pharmacy studies, develops and manufactures herbal and biological medicines which
its sells through distribution channels in China.  Its operations, including a production line which
was imported from Taiwan, are located in the Torch High Development Zone of Xiamen, China.
The operations of Tian'an Pharmacy, and the Japonica Capsule, which is currently its principal
product line, have both obtained China GMP approval.  The Company believes this will be an
important factor in the level of success which can be achieved for the operations of Tian'an
Pharmacy because the Chinese government requires all hospitals and pharmacies in China to use
GMP approved medicine or medicine produced by GMP approved companies.

At the present time, Tian'an Pharmacy produces a total of ten different herbal and biological
medicines which are sold in China.  Its most well known products are  Japonica capsules, which are
used to help increase the body's immunity function, and to treat cancer cells in the body, and bear
bile capsules, which are used to treat liver diseases and high blood pressure.  Research into new
products and treatments is ongoing at Tian'an Pharmacy.   This research focuses primarily on
combining various herb resources with advanced technology to produce new herbal medicines.
Linglong capsules, a new product line used to treat liver cancel cells, are currently under final
development and are expected to receive approval from the Chinese government during 2001.

Research into new products is ongoing at Tian'an Pharmacy.  This research is focused on
studying, developing and producing herbal medicines which will be intended to be marketed and
sold in China and in North America.

**Risk Factors**

An investment in the outstanding securities of the Company should be considered to be risky.
The following discussion of risk factors is not intended to provide an exhaustive list of all of the
risks which may be associated with an investment in the Company.   Any person considering such
an investment should carefully consider all of the risks involved, including, but not limited to, the
risk factors discussed below, before making an investment decision.

Limited Operating History.    The Company was formed in December, 1998, and itself has
no operating history or revenues from operations. On April 30, 2000, it acquired all of the issued and
outstanding stock of TZF International Herbs Investment, Inc, and in December, 2000, it acquired
Tian'an Pharmacy, TZF International Herbs (Jiangsu) Co, Ltd., and Shenzhen Tianzifu Network
Technology, Ltd.  Although several of the entities acquired by the Company have established a
profitable operating history, there is no assurance the Company will be able to successfully manage
and integrate their operations or that they will continue to be profitable.  As a result,  the Company
faces all of the risks inherent in a new business venture, including all the unforeseen costs, expenses,
problems, and difficulties to which such ventures are subject.

No Market for Stock.  At the present time, there is no public market for the Company's
common stock and there is no assurance that a market will develop in the future.  Although the
Company intends to take steps to have its shares approved for trading on the OTC Bulletin Board,
there is no assurance that it will be successful.  Even if a market should develop in the future, there
is no assurance that it will be maintained.   Thus, persons who purchase shares of the Company may
find it to be difficult or impossible to liquidate their investment, because of the lack of a market or
the difficulty in maintaining a market.  There is currently no person or entity which is obligated to
make or maintain a market in the Company's shares.

Need for Additional Financing.	The Company will require substantial additional funds
to continue its acquisition and market expansion plans.   Although the Company's Chairman, Mr.
Xin Chen, has previously provided substantial funds to the Company to assist incompletion of
acquisitions, and has indicated a willingness and ability to provide some additional funds to the
Company in the future until the Company is in a position to raise funds from external sources,  he
is not obligated to provide additional funds in the future and there is no assurance that he will be able
to do so.  Likewise,  there is no assurance that the Company will be able to raise funds from external
sources when it seeks to do so. Therefore, no assurance can be given that additional financing will
be available when needed or that such financing will be available on terms acceptable to the
Company.  If adequate funds are not available, the Company would be required to delay, trim or
eliminate its expansion plans, its research and product development programs or other programs or
services which are currently part of the business plan, or may be required to alter the business plan,
which is likely to have a material adverse effect on the Company.

Dependence on Key Personnel.  The success of the Company will depend to a significant
degree upon the ability of its senior management personnel to integrate and consolidate the
operations of its various subsidiaries.   It will also depend to a significant degree on the Company's
ability to retain and integrate a substantial number of the management personnel previously
employed by its subsidiaries.  Significant disruption in the Company's operations would occur if it
is not able to retain its senior management personnel and to fully integrate and develop cooperation
between the separate management personnel of each of its subsidiaries.  The Company does not
currently have employment contracts with any of its senior management personnel.  As a result,
those persons could elect to terminate their employment with the Company at any time.

Governmental Regulation.  There are substantial regulations applicable to the import and
export of goods and relating to advertising and sale of food products or over-the-counter medicines
both in North America and in China.  The Company believes that it currently has all of the necessary
permits to manufacture and sell its existing products in China.   However, as it seeks to develop new
products and to expand its marketing and distribution networks both in China and in North America,
it is likely to encounter additional regulations.   Although it is the Company's intention to comply
with all applicable governmental regulations in every country in which it conducts operations, there
is no assurance that it will be able to do so.  There is also no assurance that the applicable regulations
in the various countries in which the Company seeks to operate will be consistent.  Finally, there is
no assurance that the Company will have the resources necessary to comply with certain regulations
such as those required to seek approval to sell certain of its products in the U.S., Canada, or other
countries as over-the-counter medicine.    The process of obtaining approval for sale of any product
as an over-the-counter medicine is extremely expensive and time-consuming.

Patent or Copyright Protection.	The Company's success will depend upon its ability
to obtain patents, obtain exclusive rights to patents, maintain trade secret protection and operate
without infringing upon the proprietary rights of third parties.  The Company has attempted to
protect its products and technologies through a combination of patent and trade secret laws and will
continue to do so in the future.  There can be no assurance that the Company's efforts will be
successful or that competitors will not develop functionally equivalent or superior products or
technology that does not infringe the Company's patents or trade secrets.   Accordingly, the
Company may be vulnerable to competitors which develop competing products or competing
technology, whether independently, or as a result of acquiring access to the Company's trade secrets.

Competition.	Until recently, the Chinese health food market (including manufacturing as
well as wholesale and retail distribution and sales) has not been open to foreign investors and the
Company does not believe that there are currently any national chain stores or other national outlets
for the distribution and sale of Chinese health food products in all regions of  China.  However,  it
is believed that the domestic China health food market will open to foreign competition soon after
China joins the World Trade Organization (W.T.O.).   As a result, it is anticipated that many large
foreign competitors are likely to seek to enter the Chinese market in the near future.  The expected
increase in foreign competition, combined with competition from both existing and newly
established domestic entities, will make the Chinese health food market extremely competitive. The
Company hopes to create a competitive edge for itself in China by quickly establishing a large
distribution network for its health food products.  It has obtained government approval to establish
health food counters in up to 200 department stores in China and up to 50 pharmacy stores in the
province of Shanxi, as well as approvals to establish up to 20 pharmaceutical and health food sales
centers and up to 60 health food stores for sale of both Chinese and North American products.  In
addition to its plans to expand its distribution network in China, the Company also intends to seek
to expand its operations and increase sales of its Chinese health food products in North America.
There is no assurance that the Company will be able to complete its expansion plans or that it will
be able to compete effectively in China against both domestic and foreign competition.  Likewise,
since the Company has only a limited operating history with little revenue from its current operations
in North America, there is no assurance it will able to effectively introduce and sell its Chinese
health food products in the North American market.

Research and Development.	The Company will be required to expend a significant amounts
of money on research and development expenses in order to develop new products improve the
market acceptance of its existing products.  There is no assurance that it will have sufficient capital
to fund all desired  research and development activities or that the research and development
activities its does conduct will lead to the creation of new products.  is necessary in order to In order
to be successful in the market for sale of pharmaceutical and health food products, the Company will
be required to

Market Acceptance.	Many Chinese health food products are not currently widely used
outside of China.  There is no assurance that the Company's products, if approved for sale in the
North American market and other countries as either food products or over-the-counter medicines,
will achieve market acceptance.  The extent of acceptance of the Company's products by consumers
and by persons in the healthcare industry will depend upon a number of factors, including, but not
limited to, recognition of the efficacy of the product, product availability, brand name recognition,
the availability and cost of competitive products, relative safety and efficacy of competitive products,
and the like.   There is no assurance that the Company's products will be successful in achieving
market acceptance as either a food product or as an over-the-counter medicine.

Potential Product Liability.	Testing and proposed commercialization of food products and
human therapeutic products involves inherent risk of product liability claims and associated adverse
publicity.  There can be no assurance that the Company will be able to obtain or maintain sufficient
insurance coverage on acceptable terms with coverage which is adequate to provide necessary
protection. Such insurance is expensive, difficult to obtain and may not be available in the future on
acceptable terms, or at all.  An inability to obtain sufficient insurance coverage on reasonable terms
or to otherwise protect against potential product liability claims, could prevent or inhibit the
commercialization of the Company's potential products.

Manufacturing Uncertainties.	The Company's ability to commercialize its products will
depend upon its ability to manufacture such products, either directly or through third parties, at a
competitive cost and in accordance with any applicable regulatory requirements.  The Company's
products must be manufactured in commercial quantities at an acceptable cost and with sufficient
quality, consistency, purity and stability to make them marketable.  If the Company is unable to make
manufacture its products in sufficient quantities and at a competitive cost,  either in its own
manufacturing facilities or through contracting with third parties, it would have a material adverse
affect upon the Company's business and potential profitability.

ITEM 2.	DESCRIPTION OF PROPERTY.

The Company currently maintains a mailing address at Unit 1, 3071 No. 5 Road, Richmond,
B.C., Canada V6X 2T4. The Company's telephone number there is (604) 718-2188.  Other than this
mailing address, the Company does not maintain any other office facilities, and does not anticipate
the need for maintaining office facilities at any time in the foreseeable future. The Company pays
rent in the amount of CAD $3,300 (approximately $2,220 U.S. dollars)  per month for the use of this
office space. The lease is for three years, and commenced on July 1, 1999.

The operations of Tian'an Pharmacy are located in a 7,100 square meter building in the Torch
High Development Zone of Xiamen, China.

The operations ofT.Z.F. International Herbs (Jiangsu) Co., Ltd.(formerly Second Factory
Pharmacy) are located in a  20,000 square meter building in Yancheng City in Jiangsu Province.  It's
facility includes a factory area of 20,000 square meters and office area of 8,500 square meters.

The facilities of Shenzhen Tianzifu Network Technology Ltd., are located at  8 South Road,
Dong Men, LouHu District, Shenzhen****City, GuangDong Province.    Its subsidiary, Shanxi Medicine
Materials Supply Company occupies 700 square meters of office space and an 800 square meter
warehouse in Taiyuan City in Shanxi Province.

ITEM 3.	LEGAL PROCEEDINGS.

Expediter Sales Ltd. ("Expediter") has filed suit against T.Z.F. International Herbs
Investments, Inc.,  alleging a breach of contract and misrepresentation.  Expediter is seeking damages
for alleged loss of profits, loss of business and goodwill, misrepresentation, set-up expenses and the
alleged wrongful use of Expediter's name.  Further, Expediter is seeking an injunction to prevent the
T.Z.F. Herbs from selling herbal tea in Canada.  TZF claims that it terminated its contract with
Expediter as a result of non-performance.  TZF Herbs intends to vigorously defend this suit and has
filed a counterclaim against Expediter for collection of outstanding debts.

ITEM 4.	SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

No matters were submitted to a vote of the security holders of the Company during the fourth
quarter of the fiscal year which ended December 31, 2000.



ITEM 5.	MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER
MATTERS.

As of December 31, 2000, there was not currently a public trading market for the Company's
shares.  As of December 31, 2000, the Company's securities were held of record by a total of
approximately 48 persons.

ITEM 6.	MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF
OPERATIONS.

Forward Looking Statements.	 Certain statements contained in this report, including
statements in the following discussion of the Company's Plan of Operation, which are not statements
of historical fact are what are known as "forward looking statements," which are basically statements
about the future, and which for that reason, involve risk and uncertainty, since no one can accurately
predict the future. Words such as "plans," "intends," "will," "hopes," "seeks," "anticipates,"
"expects," "goal" and "objective" often identify such forward looking statements, but are not the
only indication that a statement is a forward looking statement. Such forward looking statements
include statements of our plans and objectives with respect to the  present and future operations of
the Company,  and statements which express or imply that such present and future operations will
or may produce revenues, income or profits. Numerous factors and future events could cause the
Company to change such plans and objectives, or fail to successfully implement such plans or
achieve such objectives, or cause such present and future operations to fail to produce revenues,
income or profits.

Background.	The Company's business plan is to build a vertically and horizontally
integrated network of health food distribution centers and retail counters in China that will sell
products both under the T.Z.F. brand name and under other Chinese and Western brand names.  The
Company also intends to introduce several of its Chinese health food products to the North American
market.

During the fiscal year ended December 31, 2000, the Company completed five acquisitions
and entered into a contract for a sixth acquisition.  The acquisition of T.Z.F. International Herbs
Investment, Inc., a British Columbia corporation, was completed in April, 2000.  As a result, its
operations were under the control of the Company for a significant portion of the year.  However,
the acquisitions of Tian'an Pharmacy (Xiamen) Co, Ltd., T.Z.F. International Herbs (Jiangsu) Co,
Ltd. (formerly Second Factory Pharmacy ofYangheng City), and Shenzhen Tianzifu Network
Technology Ltd.(and through it, the acquisition ofGuangdong Hongkang Pharmaceutical Company)
were not completed until December, 2000.  Therefore, during the fiscal year ended December 31,
2000, the Company was not involved in management of the operations of any of these subsidiaries.

Finally, during the 2000 fiscal year,  the Company entered into a contract to acquire Shanxi Medicine
Materials Supply and Marketing Company.  As of the date of this report this acquisition was still in
process.   Through its subsidiary, Shenzhen Tianzifu, the Company intends to complete the
acquisition of Shanxi Medicine during 2001.

The Company believes that, on an overall basis, the operations of its subsidiaries will be
profitable during the fiscal year ending December 31, 2001.  However,  the Company plans to work
on enhancing and improving its profitability during the year through integration of the operations
of its 6 subsidiaries.  It also intends to seek to facilitate the establishment of a public trading market
for its outstanding common stock and to seek to raise approximately US $68 million in additional
capital to be used to expand the operations of its subsidiaries.   There is no assurance that the funds
the Company intends to raise will be available on any basis, or that they will be available on terms
on conditions satisfactory to the Company.

Plan of Operations.	The Company plans to invest a total of up to US $68 million into its
subsidiaries by the end of 2001.  These funds are expected to be raised in two traunches through
private placement of securities, public financings and/or loans or additional investments from
existing shareholders.  The Company intends to seek to raise the first traunchUS $8 million prior to
the end of May, 2001, and to raise an additional US $60 million prior to the end of 2001.

The Company has allocated the US $68 million in the following approximate amounts:

- US $17.7 million for working capital, and payment of financing and management
costs; investment in T.Z.F. Herbs for product promotion, advertising and distribution
expenditures; and for establishing a research and development laboratory in Canada.
- US $6.1 million to be investing in Shanxi Medicine to establish 50 retail outlets in
Shanxi province (each requiring an estimated initial investment of approximately US
$ 100,000) for which the Company has received government approval, and one
distribution center requiring an initial investment of approximately US $1,000,000.
- US $3.3 million to be invested in Guangdong Hongkang Medical to establish 20
wholesale outlets (each requiring an estimated initial investment of approximately
US $50,000)
- US $6.6 million to be invested in Tian'an Pharmacy for payment of research and
development expenses and for payment of marketing expenses for its new product
for liver cancer therapy (Linglong Capsules).
- US $9.2 million to be invested in T.Z.F. International Herbs (Jiangsu) Co. Ltd. for
plant expansion to increase capacity, payment of research and development expenses
and for expenses related to expansion of its distribution network.
- US $24.56 million to be invested in Shenzhen Tianzifu primarily for payment of
costs associated with establishing sales counters in 200 department stores in China
(each requiring an estimated initial investment of approximately $US $50,000), and
for payment of costs associated with establishing 60 retail stores for sale of both
Chinese and North American brands.  The Company has received government
approval for establishing both the sales counters and the retail stores.



There is no assurance that the Company will be able to raise all, or any substantial portion
the of funds required to carry out its plan of operations for fiscal 2001.  In the event the Company
is not able to raise all, or a substantial portion of the funds, it will be required to limit its expansion
plans, and to substantially modify its plan of operations.

ITEM  7.	FINANCIAL STATEMENTS AND EXHIBITS

Index to Financial Statements - December 31, 2000 and December 31, 1999.

i)     Independent Auditors' Report - T.Z.F. International Investments, Inc., (formerly Sabai Sabai
Enterprises Corp.)

ii)     T.Z.F. International Investments, Inc., (formerly Sabai Sabai Enterprises Corp.), Consolidated
Balance Sheets, December 31, 2000 and 1999

iii)     T.Z.F. International Investments, Inc., (formerly Sabai Sabai Enterprises Corp.), Consolidated
Statements of Operations

iv)     T.Z.F. International Investments, Inc., (formerly Sabai Sabai Enterprises Corp.), Consolidated
Statements of Cash Flows, from date of inception on September 15, 1998, to December 31, 2000

v)     T.Z.F. International Investments, Inc., (formerly Sabai Sabai Enterprises Corp.), Schedule of
Balance Sheet Items as at December 31, 2000

vi)     T.Z.F. International Investments, Inc., (formerly Sabai Sabai Enterprises Corp.), Consolidated
Statement of Changes in Stockholders' Equity, from date of inception on September 15, 1998, to
December 31, 2000

vii)     T.Z.F. International Investments, Inc., (formerly Sabai Sabai Enterprises Corp.), Notes to
Consolidate Financial Statements

INDEPENDENT AUDITOR'S REPORT

To the Directors and Stockholders of T.Z.F. International Investments, Inc. (formerly Sabai Sabai
Enterprises Corp.) (A Nevada Corporation) (A Development Stage Company)

We have audited the Consolidated Balance Sheet of T.Z.F. International Investments, Inc.
(formerly Sabai Sabai Enterprises, Corp.) (A Nevada Corporation) (A Development Stage
Company) and subsidiaries as of December 31, 2000, and the related Consolidated Statements of
Operations, Cash Flows and Changes in Stockholders' Equity for the year then ended.  These
financial statements are the responsibility of the Company's management.  Our responsibility is
to express an opinion on these financial statements based on our audit.   The financial statements
for subsidiary companies in China were audited by other auditors whose reports have been
furnished to us, and our opinion, insofar as it relates to the amounts included for  subsidiary
companies, is based on the report of the other auditors.  We attended at the subsidiary operations
in China and conducted such audit tests and examinations as we considered necessary.  The
financial statements of T.Z.F. International Investments, Inc. (formerly Sabai Sabai Enterprises,
Corp.) as of December 31, 1999, were audited by other auditors whose report dated February 4,
2000, expressed an unqualified opinion on these statements, except that they added a going
concern assumption stating that the Company will require an infusion of capital to sustain itself.
This going concern assumption and cash infusion requirement does not apply as at December 31,
2000.

We conducted our audit in accordance with generally accepted auditing standards.  Those
standards require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement.  An audit includes examining,
on a test basis, evidence supporting the amounts and disclosures in the financial statements.  An
audit also includes assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.  We believe that
our audits and the report of other auditors provide a reasonable basis for our opinion.

In our opinion, based on our audit and the report of other auditors, the consolidated financial
statements referred to above present fairly, in all material respects, the financial position of
T.Z.F. International Investments, Inc. as of December 31, 2000, and the results of its operations
and its cash flows for the year then ended in conformity with U.S. generally accepted accounting
principles (GAAP).

Moen and Company

Chartered Accountants

Vancouver, British Columbia

February 28, 2001

T.Z.F. INTERNATIONAL INVESTMENTS, INC.

(Formerly Sabai Sabai Enterprises Corp.)

(A Nevada Corporation)

Consolidated Balance Sheets

December 31, 2000 and 1999

(In US Dollars)

|                                                                                                                                   | 2000        | 1999          
|---------------------------------------------------------------------------------------------------------------------------------- | ----------- | --------------
|**ASSETS**                                                                                                                         |             |               
|Current assets                                                                                                                     |             |               
|Cash and cash equivalents (note 3)                                                                                                 | $1,668,711  | $       54,370
|Accounts receivable (note 4)                                                                                                       | 5,204,977   | -             
|Prepaid expenses and deposits (note 5)                                                                                             | 34,684      | -             
|Subscriptions receivable (note 6)                                                                                                  | 406,434     | -             
|Short-term investment - secured (note 29)                                                                                          | 1,354,293   | -             
|Inventories, at lower cost or market (note 7)                                                                                      | 1,244,642   | -             
|**TOTAL CURRENT ASSETS**                                                                                                           | 9,913,741   | 54,370        
|Investment in Guangdon Hongkang Medical Co. (note 8)                                                                               | 532,044     | -             
|Fixed Assets - Schedule A                                                                                                          | 5,876,615   | -             
|Intangible Assets - Schedule A                                                                                                     | 4,140,910   | -             
|Goodwill, at cost - (note 12)                                                                                                      | 1,206,554   | -             
|**TOTAL ASSETS**                                                                                                                   | $21,669,864 | $       54,370
|**LIABILITIES AND STOCKHOLDERS' EQUITY**                                                                                           |             |               
|Current Liabilities                                                                                                                |             |               
|Bank loans - secured (note 18)                                                                                                     | $1,579,202  | $            -
|Accounts payable and accrued (note 15)                                                                                             | 2,750,430   | 500           
|Payable on acquisition of Shenzhen Tianzhifu Network
Technology, Ltd. (note 1)                                                     | 518,590     | -             
|Management fees payable (note 16)                                                                                                  | 150,004     | -             
|Due to related parties, unsecured, non interest bearing, with
no specific terms of repayment (note 17(b))                          | 515,053     | -             
|**TOTAL CURRENT LIABILITIES**                                                                                                      | 5,513,279   | 500           
|Long-term Liabilities                                                                                                              |             |               
|Long-term (note 19)                                                                                                                | 306,138     | -             
|Deferred liabilities - pension (note 24)                                                                                           | 212,562     | -             
|                                                                                                                                   | 518,700     | -             
|Stockholders Equity                                                                                                                |             |               
|Capital stock (note 20)                                                                                                            |             |               
|Authorized, 100,000,000 common shares at $0.0001 par
value; issued, 35,897,309 common shares (1999 - 1,600,000
shares) - par value | 3,590       | 1,600         
|Paid in capital in excess of par value of stock                                                                                    | 15,225,943  | 60,900        
|Retained earnings (deficit), accumulated during the
development stage                                                              | 403,969     | (8,630)       
|Cumulative translation (note 2)                                                                                                    | 4,383       | -             
|                                                                                                                                   | 15,637,885  | 53,870        
|**TOTAL LIABILITIES AND STOCKHOLDERS'
EQUITY**                                                                                     | $21,669,864 | $       54,370

See accompanying notes and independent auditors' report.

T.Z.F. INTERNATIONAL INVESTMENTS, INC.

(Formerly Sabai Sabai Enterprises Corp.)

(A Nevada Corporation)

Consolidated Statements of Operations

(In US Dollars)

|                                                                          | Cumulative from
Inception Date of
Sep. 15, 1998 to
December 31,

2000 | Quarter ended
December 31,

2000 | Quarter ended
December 31,

1999 | Year ended
December
31,

2000 | Year ended
December
31,

1999
|------------------------------------------------------------------------- | --------------------------------------------------------------------- | -------------------------------- | -------------------------------- | ----------------------------- | -----------------------------
|Revenue                                                                   |                                                                       |                                  |                                  |                               |                              
|Sales                                                                     | $1,868,276                                                            | $1,595,677                       | $                  -             | $1,868,276                    | $                -           
|Cost of sales                                                             | 887,649                                                               | 618,131                          | -                                | 887,649                       | -                            
|                                                                          | 980,627                                                               | 977,546                          | -                                | 980,627                       | -                            
|Other income                                                              | 228,420                                                               | 226,549                          | 598                              | 227,464                       | 956                          
|                                                                          | 1,209,047                                                             | 1,204,095                        | 598                              | 1,208,091                     | 956                          
|Administration costs                                                      | 552,678                                                               | 34,294                           | 846                              | 543,092                       | 8,471                        
|Stock-based
compensation                                                  | 252,400                                                               | -                                | -                                | 252,400                       | -                            
|                                                                          | 805,078                                                               | 34,294                           | 846                              | 795,492                       | 8,471                        
|Profit (loss) for the
period                                              | $403,969                                                              | $1,169,801                       | $   (248)                        | $ 412,599                     | $   (7,515)                  
|Basic and diluted
profit per share                                        |                                                                       | $        0.04                    | $          (0.00)                | $        0.02                 | $        (0.00)              
|Weighted average
number of common
shares used to
compute profit per
share |                                                                       |                                  |                                  |                               |                              
|Basic and Diluted                                                         |                                                                       | 29,153,909                       | 6,000,000                        | 17,717,212                    | 6,000,000                    

See accompanying notes and independent auditors' report.

T.Z.F. INTERNATIONAL INVESTMENTS, INC.

(Formerly Sabai Sabai Enterprises Corp.)

(A Nevada Corporation) (A Development Stage Company)

Consolidated Statement of Cash Flows

(In US Dollars)

|                                          | Cumulative from
Inception Date of
Sep. 15, 1998 to
December 31,

2000 | Quarter ended
December 31,

2000 | Quarter ended
December 31,

1999 | Year ended
December
31,

2000 | Year ended
December
31,

1999
|----------------------------------------- | --------------------------------------------------------------------- | -------------------------------- | -------------------------------- | ----------------------------- | -----------------------------
|Cash derived from
(used for)              |                                                                       |                                  |                                  |                               |                              
|Operating Activities                      |                                                                       |                                  |                                  |                               |                              
|Profit (loss) for the
period              | $ 403,969                                                             | $1,169,801                       | $     (248)                      | $ 412,599                     | $ (7,515)                    
|Items not requiring
use of cash           |                                                                       |                                  |                                  |                               |                              
|Depreciation                              | 13,951                                                                | 8,089                            | -                                | 13,591                        | -                            
|Stock-based
compensation                  | 252,400                                                               |                                  | -                                | 252,400                       | -                            
|Cumulative translation                    | 4,383                                                                 | 3,811                            | -                                | 4,383                         | -                            
|Changes in non-cash
working capital items |                                                                       |                                  |                                  |                               |                              
|Accounts receivable                       | (5,204,977)                                                           | (4,910,754)                      | -                                | (5,204,977)                   | -                            
|Prepaid expenses and
deposits             | (34,684)                                                              | (29,300)                         | -                                | (34,684)                      | -                            
|Inventories                               | (1,244,642)                                                           | (1,244,642)                      | -                                | (1,244,642)                   | -                            
|Subscriptions
receivable                  | (406,434)                                                             | (3,812)                          | -                                | (406,434)                     | -                            
|Accounts payable and
accrued              | 2,750,430                                                             | 2,661,350                        | 500                              | 2,749,930                     | 126                          
|Advances on
inventory purchase            |                                                                       | 102,511                          | -                                | -                             | -                            
|                                          | (3,465,964)                                                           | (2,242,946)                      | 252                              | (3,457,834)                   | (7,389)                      
|Financing activities                      |                                                                       |                                  |                                  |                               |                              
|Issuance of shares for
cash               | 7,605,801                                                             | 5,264,000                        | -                                | 7,543,301                     | 60,000                       
|Net gain on
acquisition                   | 3,333,103                                                             | 3,333,103                        | -                                | 3,333,103                     | -                            
|Management fees
payable                   | 150,004                                                               | (35,720)                         | -                                | 150,004                       | -                            
|Payable on
acquisitions                   | 518,590                                                               | 518,590                          | -                                | 518,590                       | -                            
|Bank loans                                | 1,579,202                                                             | 1,579,202                        | -                                | 1,579,202                     | -                            
|Long-term debt                            | 306,138                                                               | 306,138                          | -                                | 306,138                       | -                            
|Deferred liabilities,
pension             | 212,562                                                               | 212,562                          | -                                | 212,562                       | -                            
|Due to related parties                    | 515,053                                                               | (394,641)                        | -                                | 515,053                       | -                            
|                                          | 14,220,453                                                            | 10,783,234                       | -                                | 14,157,953                    | 60,000                       
|Investing activities                      |                                                                       |                                  |                                  |                               |                              
|Fixed assets required                     | (5,890,206)                                                           | (5,809,083)                      | -                                | (5,890,206)                   | -                            
|Intangible assets                         | (102,681)                                                             | (102,681)                        |                                  | (102,681)                     |                              
|Goodwill                                  | (1,206,554)                                                           | (1,206,554)                      | -                                | (1,206,554)                   | -                            
|Investment in
Hongkang                    | (532,044)                                                             | (532,044)                        | -                                | (532,044)                     | -                            
|Short-term investment                     | (1,354,293)                                                           | (1,354,293)                      | -                                | (1,354,293)                   | -                            
|Deposits on proposed
acquisitions         |                                                                       | 1,824,924                        | -                                | -                             | -                            
|                                          | (9,085,778)                                                           | (7,179,731)                      | -                                | (9,085,778)                   | -                            
|Cash, increase during
the period          | 1,668,711                                                             | 1,360,557                        | 252                              | 1,614,341                     | 52,611                       
|Cash, beginning of
period                 |                                                                       | 308,154                          | 54,118                           | 54,370                        | 1,759                        
|Cash, end of period                       | $1,668,711                                                            | $1,668,711                       | $ 54,370                         | $1,668,711                    | $ 54,370                     

See accompanying notes and independent auditors' report.

T.Z.F. INTERNATIONAL INVESTMENTS, INC.

(Formerly Sabai Sabai Enterprises Corp.)

(A Nevada Corporation)

Schedule of Balance Sheet Items

As at December 31, 2000

(In US Dollars)

|                                    | Cost       | Accumulated
Depreciation | Net        
|----------------------------------- | ---------- | ------------------------ | -----------
|Fixed Assets                        |            |                          |            
|Deferred lease expense              | $   3,556  | $               -        | $     3,556
|Fixed assets of operating companies |            |                          |            
|- note 9                            | 2,861,731  | 756,756                  | 2,104,975  
|- note 10                           | 239,261    | -                        | 239,261    
|Construction in progress - Note 11  | 1,918,374  | -                        | 1,918,374  
|Rights of use of land               |            | -                        |            
|Tianan                              | 370,508    | -                        | 370,508    
|TZF Jiangsu                         | 1,239,941  | -                        | 1,239,941  
|                                    | $6,633,371 | $ 756,756                | $5,876,615 
|Intangible Assets                   |            |                          |            
|Technology rights - note 14         |            |                          | $4,038,229 
|Deferred costs - Note 13            |            |                          | 102,681    
|                                    |            |                          | $4,140,910 

See accompanying notes and independent auditors' report.

T.Z.F. INTERNATIONAL INVESTMENTS, INC.

(Formerly Sabai Sabai Enterprises Corp.)

(A Nevada Corporation) (A Development Stage Company)

Consolidated Statement of Changes in Stockholders' Equity

From Date of Inception on September 15, 1998 to December 31, 2000

(In US Dollars)

|                                                                                  | Number of
common
shares | Par
value | Additional
paid-in
capital | Total
Capital
Stock | Deficit
accumulated
during the
development
stage | Cumulative
Translation | Total
stockholders'
equity
|--------------------------------------------------------------------------------- | ----------------------- | --------- | -------------------------- | ------------------- | ------------------------------------------------ | ---------------------- | --------------------------
|9/25/98
issuance of
common stock
for cash                                         | 1,000,000               | $1,000    | $1,500                     | $2,500              |                                                  |                        | $2,500                    
|Net loss for the
year ended
December 31,
1998                                     |                         |           |                            |                     | (1,115)                                          |                        | (1,115)                   
|Balance,
December 31,
1998                                                        | 1,000,000               | 1,000     | 1,500                      | 2,500               | (1,115)                                          |                        | 1,385                     
|2/17/99
issuance of
common stock
for cash                                         | 600,000                 | 600       | 59,400                     | 60,000              |                                                  |                        | 60,000                    
|Net loss for the
year ended
December 31,
1999                                     |                         |           |                            |                     | (7,515)                                          |                        | (7,515)                   
|Balance,
December 31,
1999                                                        | 1,600,000               | 1,600     | 60,900                     | 62,500              | (8,630)                                          |                        | 53,870                    
|4/30/00
cancellation of
common stock
and transfer of
par value to
paid-in capital | (1,000,000)             | (1,000)   | 1,000                      |                     |                                                  |                        |                           
|Balance, April
30, 2000 before
forward split                                      | 600,000                 | 600       | 61,900                     | 62,500              | (8,630)                                          |                        | 53,870                    
|5/15/00 10 to 1
forward split                                                     | 6,000,000               | 600       | 61,900                     | 62,500              | (8,630)                                          |                        | 53,870                    
|5/15/00
issuance of
common stock
for services                                     | 250,000                 | 25        | 252,375                    | 252,400             |                                                  |                        | 252,400                   
|5/15/00
issuance of
common stocks
for the BC
Company                              | 18,451,843              | 1,845     | 5,351,087                  | 5,352,932           |                                                  |                        | 5,352,932                 
|7/4/00 issuance
of common
stock for cash                                          | 340,000                 | 34        | 343,216                    | 343,250             |                                                  |                        | 343,250                   
|9/30/00
issuance of
common stock
for cash                                         | 615,466                 | 62        | 621,286                    | 621,348             |                                                  |                        | 621,348                   
|10/19/00
issuance of
common stock
for cash                                        | 10,000                  | 1         | 10,999                     | 11,000              |                                                  |                        | 11,000                    
|11/19/00
issuance of
common stock
for cash                                        | 230,000                 | 23        | 252,977                    | 253,000             |                                                  |                        | 253,000                   
|12/28/00
issuance of
common stock
for debt                                        | 10,000,000              | 1,000     | 4,999,000                  | 5,000,000           |                                                  |                        | 5,000,000                 
|Net profit for
the year ended
December 31,
2000                                   |                         |           |                            |                     | 412,599                                          |                        | 412,599                   
|Negative
goodwill - gain
on acquisition
TZF Jiangsu -
note 1                      |                         |           | 3,333,103                  | 3,333,103           |                                                  |                        | 3,333,103                 
|Cumulative
translation                                                            |                         |           |                            |                     |                                                  | 4,383                  | 4,383                     
|Balance,
December 31,
2000                                                        | 35,897,309              | $3,590    | $15,225,943                | $15,229,533         | $403,969                                         | $4,383                 | $15,637,885               

See accompanying notes and independent auditors' report.

T.Z.F. INTERNATIONAL INVESTMENTS, INC.

(Formerly Sabai Sabai Enterprises Corp.)

(A Nevada Corporation) (A Development Stage Company)

NOTES TO CONSOLIDATED STATEMENTS

December 31, 2000

(In U.S. Dollars)

Note 1.	     ORGANIZATION AND NATURE OF BUSINESS

The Company was incorporated under the laws of the State of Nevada on September 15, 1998, as
Sabai Sabai Enterprises, Corp.

Pursuant to a stock purchase agreement March 30, 2000, T.Z.F. International Herbs Investment Inc.,
("BC Company") purchased 1,000,000 shares of the issued and outstanding common stock of the
Company.  These shares were purchased in anticipation of the subsequent completion of a share
exchange transaction between the Company and the BC Company.  In conjunction with completion
of the share exchange transaction, these shares were cancelled effective April 30, 2000 and as a
result the amount of the par value of $1,000 was transferred to paid-in capital.

Pursuant to the terms of the share exchange, the Company acquired all of the issued and outstanding
stock of the BC Company in exchange for the issuance of 18,451,843 shares of its authorized but
previously unissued shares of common stock, which shares were valued at $5,352,932 for purposes
of theacquisition.  Assets and liabilities of the BC Company at the date of acquisition on April 30,
2000, were as follows:

|Assets                                                                                                                    |           
|------------------------------------------------------------------------------------------------------------------------- | ----------
|Cash and short-term deposits                                                                                              | $1,040,372
|Accounts receivable                                                                                                       | 13,217    
|Capital stock subscriptions receivable                                                                                    | 374,546   
|Prepaid expense and deposit                                                                                               | 5,382     
|Inventories                                                                                                               | 206,532   
|Deferred lease expense, net of amortization                                                                               | 5,047     
|Fixed assets, net                                                                                                         | 59,927    
|Intangible assets, technology rights                                                                                      | 4,038,229 
|                                                                                                                          | 5,743,252 
|Liabilities                                                                                                               |           
|Accounts payable and accrued                                                                                              | 114,917   
|Accrued payroll deductions payable                                                                                        | 45,767    
|Management fees payable                                                                                                   | 168,205   
|Due to related parties                                                                                                    | 60,755    
|                                                                                                                          | 389,644   
|Net assets including cumulative translation                                                                               | 5,353,608 
|Cumulative translation, included in above, booked
in stockholders' equity of Sabai Sabai                                  | (676)     
|Net value in exchange for 18,451,843 common
shares of Sabai Sabai and net equity on date of
acquisition of the BC Company | $5,352,932

In May 2000, the Company completed a 10:1 forward split of its outstanding stock. This forward
split increased the number of issued and outstanding shares from 600,000 (1,600,000 previously
outstanding less the 1,000,000 shares which were cancelled) to 6,000,000.  Subsequent to
completion of the share exchange on April 30, 2000, the BC Company (the Company's wholly-owned subsidiary) received subscriptions for 340,000 additional shares.  The Company elected to
convert such shares to shares of its own common stock on the same terms as it completed the
share exchange.  Therefore, effective as of July 4, 2000, the Company issued 340,000 additional
shares in exchange for shares of the BC Company.  In May 2000, following completion of the
forward split the Company authorized the issuance of 250,000 restricted shares as compensation
for consulting services at a price of CAD$1.50 per share to the following:

|Name           | Number of Shares | Consideration Cad$ | Equivalent to US$
|-------------- | ---------------- | ------------------ | -----------------
|Robert Gelfand | 50,000           | $ 75,000           | $ 50,480         
|Fred Fisher    | 200,000          | $300,000           | $201,920         
|               | 250,000          | $375,000           | $252,400         

T.Z.F. International Herbs Investment Inc., which is now a wholly-owned subsidiary of the
Company, owns the formula and all distribution and intellectual property rights, including trademark,
patent and industry design rights, for Snow Lotus Tea products.  The Company and its wholly-owned
subsidiary, the BC Company, are both based in Richmond, British Columbia, Canada.

On December 21, 2000, the BC Company acquired 100% of issued and outstanding shares of Tianan
Investment Limited ("Tian'an"), a British Virgin Islands company with an office in Hong Kong, for
the total price of HK$21,500,000 (US$2,758,847), which was paid in cash in three installments.  The
BC Company paid the first installment totaling HK $6,638,318.09 (approximately US $851,100) in
two parts, on July 7 and July 10, 2000. The second installment of HK $6,261,681.91 (approximately
US $802,800), and the final installment of HK$8,600,000.00 (approximately US $1,104,947), which
were paid on October 20, 2000 and December 20, 2000, respectively, were both paid by Xin Chen,
one of the principal shareholders.

The sole asset of Tian'an is its 100% ownership of Tian'an Pharmacy (Xiamen) Co., Ltd. ("Tian'an
Pharmacy"), a manufacturer of Chinese biological and herbal medicine products. Tian'an Pharmacy
has a plant which is located in the Torch High Tech Development Zone of Xiamen, China, where
it currently conducts research and development and produces herbal and biological medicines which
its distributes and sells in China.  As a result of the closing of this purchase transaction, Tian'an
became our wholly-owned subsidiary.

Assets and liabilities of Tianan  at the date of acquisition on December 21, 2000, were as follows:

|**ASSETS**                            |           
|------------------------------------- | ----------
|Cash and cash equivalents             | $103,910  
|Accounts receivable, trade            | 198,910   
|Short-term loans                      | 831,875   
|Prepaid expense and deposit           | 5,069     
|Inventories                           | 449,147   
|Deferred expense, net of amortization | 27,957    
|Fixed assets, net of amortization     | 1,405,851 
|Rights of use land - 50 years         | 370,508   
|                                      | 3,393,227 
|**LIABILITIES**                       |           
|Accounts payable, trade               | 9,921     
|Accounts payable, others              | 42,176    
|Taxes payable                         | 33,222    
|Deferred liabilities, pension         | 212,562   
|Bank loan                             | 483,676   
|                                      | 781,557   
|**NET ASSETS**                        | 2,611,670 
|Goodwill on acquisition               | 147,177   
|Total cash payments on acquisition    | $2,758,847

On December 31, 2000, the Company completed the purchase of all of the assets of T.Z.F.
International Herbs (Jiangsu) Co. Ltd. ("TZF Jiangsu") (formerly Second Pharmacy Factory of
Yancheng City), ("Second Pharmacy"), a Chinese corporation. The assets were purchased from
The People's Government of JianWu County, JiangSu Province, the People's Republic of China.
The purchase was completed pursuant to the terms of an Acquisition and Investment Agreement
dated September 12, 2000.

In accordance with the Acquisition and Investment Agreement, the purchase price was a total of
RMB14,000,000.00 (US $1,786,591), which was paid in cash in two installments, plus
assumption of liabilities totaling approximately RMB400,000 (approximately US$48,000). The
first cash installment totaling RMB3,000,000.00 (approximately US $362,000) , was paid on
September 18, 2000. The second cash installment of RMB11,000,000.00 (approximately US
$1,376,591) was paid in two parts, on November 22 and November 28, 2000.  The purchase
price for the assets of TZF Jiangsu was determined through arms length negotiation with the
seller.

The cash purchase price for the assets of TZF Jiangsu was paid on our behalf by Xin Chen, one
of the principal shareholders. These payments were part of a total of US$5,000,000 which Mr.
Chen paid or advanced on behalf of the Company during the fiscal year ended December 31,
2000.

The assets of TZF Jiangsu consist primarily of an automated assembly line used for the
production of various pharmaceutical products. The Company will continue to use them for the
production of pharmaceutical products and to seek to expand and improve the operations.

In addition to payment of the initial purchase price of RMB14,000,000 for purchase of the
existing assets of TZF Jiangsu, the Acquisition and Investment Agreement contemplates that
during the next three years we will invest an additional sum of RMB14,000,000 in fixed assets,
technological improvements, research and development and marketing in order to improve and
expand the operations of TZF Jiangsu. In return for the Company's commitment to make this
additional capital investment, the seller, The People's Government of JianWu County, JiangSu
Province, the People's Republic of China agreed to grant the Company various incentives,
including rent free occupancy of certain new plant space for 50 years, an agreement to refund
certain Value Added Tax for 3 years, a 100% exemption from income taxes for three years
commencing in 2001, a 50% exemption from income taxes for an additional 3 years thereafter,
an exemption from the Industrial and Commercial Administration Charge and other industry fees
for one year, and an exemption from a variety of other fees and surcharges during the period that
the new plant space is under construction.

Assets and liabilities of TZF Jiangsu at the date of acquisition on December 31, 2000, were as
follows:

|**ASSETS**                                                                                     |           
|---------------------------------------------------------------------------------------------- | ----------
|Cash and cash equivalents                                                                      | $1,005,456
|Accounts receivable, trade                                                                     | 1,675,847 
|Accounts receivable, others                                                                    | 701,927   
|Short-term loans                                                                               | 79,095    
|Inventories                                                                                    | 861,460   
|Construction in progress                                                                       | 1,918,374 
|Fixed assets, net of amortization                                                              | 548,421   
|Fixed assets, other                                                                            | 239,261   
|Rights of use of land - 50 years                                                               | 1,239,942 
|                                                                                               | 8,269,783 
|**LIABILITIES**                                                                                |           
|Accounts payable, trade                                                                        | 913,669   
|Accounts payable, others                                                                       | 350,001   
|Taxes payable                                                                                  | 389,934   
|Payroll and payroll deductions payable                                                         | 94,821    
|Long-term liabilities                                                                          | 306,138   
|Bank loans                                                                                     | 1,095,526 
|                                                                                               | 3,150,089 
|**NET ASSETS**                                                                                 | 5,119,694 
|Gain - negative goodwill on acquisition added
to paid-in capital in these financial statements | 3,333,103 
|Total cash payments on acquisition                                                             | $1,786,591

By an Acquisition and Investment Agreement dated December 31, 2000, the Company
completed the purchase of all of the assets of Shenzhen Tianzifu Network Technology Ltd.,
("Shenzhen TZF Net") (formerly Shenzhen Xinhaihu Industry Trading & Development Co.,
Ltd.), a Chinese corporation, and including its subsidiary, Meixian County Hengkang
Pharmaceutical Company.  The purchase price is $3,000,000, of which, $2,481,410 was paid, the
balance of $518,590 is recorded as payable on acquisition as a current liability in these financial
statements.

The major businesses of Shenzhen TZF Net are pharmaceutical businesses in China, materials
supply, computer network software and hardware development, and business information
consulting or organization.



Shenzhen TZF Net. owns and operates a major health food and medicine online sales network
through which Chinese products are marketed and brand products from North America and the
rest of the world will be distributed under licenses.  It also serves as T.Z.F's China headquarters,
as it owns one subsidiary directly, which is Meixian County Hengkang Pharmaceutical Company,
and will control the operations of all current and future T.Z.F. subsidiaries in China.

Currently, Shenzhen TZF Net operates a Chinese-language health food Web site. Its objective,
though, is to centralize the management of the entire T.Z.F. network in China and to improve its
efficiency and economic scale, including that of the manufacturing, sales and marketing
functions. It will further expand the existing distribution network and channels of all current
subsidiaries in China with its competitive edge and unique resources.  It will carry out the
T.Z.F.'s plan of building 200 chain counters and stores in the top 200 major department stores
national wide, 50 licensed drug stores, 60 chain stores and 20 distribution centers in selected
locations in China. Furthermore, once Shenzhen TZF Net has completed building the sales
network platform domestically, it will then focus on attracting international suppliers of health
food or related health care products that wish to export their products to China. It will then use
this expanding international network to market Chinese health food products and herbal
medicines. Eventually, Shenzhen TZF Net will be the flagship operation of an effective,
competitive and profitable China-North America network.

Shenzhen TZF Net will apply the computer network and database technology that it has
developed and is currently using in-house to consolidate, standardize and specialize its
management and distribution systems in order to maximize operating efficiencies. It will
implement a Retailer Management System, an Electronic Ordering System and an Electronic
Data Interchange. Network Technology's head office will control the organization of the chain
stores.  Its online network will be able to present a virtual sales platform for the eventual B2B
and B2C transaction.  In all, Shenzhen TZF Net will have seven departments: marketing,
merchandise, sales, information center, distribution center, general management/administration
and accounting.

Meixian County Hengkang Pharmaceutical Company, is a wholly owned subsidiary of Shenzhen
TZF Net. It was formed in 1995 and is located in Meixian County in Guangdong Province. It has
a staff of 60 and is one of a few pharmaceutical wholesalers/retailers (out of 990 wholesale
enterprises and 3,760 retailers) in Guangdong Province to meet the GSP requirements.
Hengkang Pharmaceutical wholesales and retails chemical pharmaceutical preparation, antibiotic
pharmaceutical preparations, Chinese traditional medicine preparations, Chinese traditional
medicine tablets and health products throughout Southern China including Guanxi, Fujian and
Hunan provinces. Hengkang Pharmaceutical plans to expand its facilities and market share in
order to meet the growing demand for medicines and to become a major pharmaceutical
distributor and wholesaler in Southern China.

Assets and liabilities of Shenzhen TZF Net at the date of acquisition on December 31, 2000,
were as follows:

|**ASSETS**                                                                                        |            
|------------------------------------------------------------------------------------------------- | -----------
|Cash and cash equivalents                                                                         | $ 416,994  
|Accounts receivable, trade                                                                        | 274,132    
|Short-term loans                                                                                  | 517,487    
|Short-term investment                                                                             | 1,354,293  
|Inventories                                                                                       | 12,033     
|Prepaid expenses                                                                                  | 23,260     
|Fixed assets, net of amortization                                                                 | 78,193     
|Investment in subsidiary, Meixian Pharmaceutical Company                                          | 532,044    
|Deferred website development costs                                                                | 74,724     
|                                                                                                  | 3,283,160  
|**LIABILITIES**                                                                                   |            
|Accounts payable, trade                                                                           | 6,829      
|Accounts payable, others                                                                          | 1,183,904  
|Taxes payable                                                                                     | 151,804    
|                                                                                                  | 1,342,537  
|**NET ASSETS**                                                                                    | 1,940,623  
|Goodwill on acquisition (note )                                                                   | 1,059,377  
|Total payments required on acquisition                                                            | $3,000,000 
|Amounts paid by December 31, 2000                                                                 | 2,481,410  
|Amount unpaid at December 31, 2000, recorded as a current
liability in these financial statements | $   518,590

Note 2.		SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

**Principles of consolidation**

The accompanying consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiary, T.Z.F. International Herbs Investment Inc., Tianan
Investment Limited (and its wholly-owned subsidiary Tianan Pharmacy (Xiamen) Co. Ltd.), TZF
International Herbs (Jiangsu) Co. Ltd. and Shenzhen Tianzhifu Network Technology Ltd.  All
significant intercompany transactions and balances have been eliminated.

******Basis of presentation**

These consolidated financial statements have been prepared in accordance with
Accounting Principles Generally Accepted in the United States ("USGAAP).

**Development stage company**

The accompanying consolidated financial statements have been prepared in accordance
with the provisions of Statement of Financial Accounting Standard No. 7, "Accounting and
Reporting by Development Stage Enterprises".

**Business Combinations**

The Company uses the Purchase Method in accounting for its acquisitions and amortizes
goodwill over a twenty-year period.

Goodwill will be subject to review for impairment.  This review would be at the lowest reporting
level or levels that include the acquired business (i.e., the reporting unit).  Goodwill would be
considered impaired and subject to write-down if the fair value of the reporting unit's goodwill is
less than its carrying amount.  The fair value of goodwill would be determined by subtracting the
fair value of the recognized net assets of the reporting unit (excluding goodwill) from the fair
value of the reporting unit.  The amount of the impairment would be the difference between the
carrying amount and the fair value of the goodwill.

**Use of estimates**

The preparation of financial statements in conformity with US GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the dates of the financial
statements and the reported amounts of revenues and expenses during the reporting periods.
Actual results could differ from those estimates.

**Cash and cash equivalents**

Cash and cash equivalents consists of cash on deposit and highly liquid short-term
interest bearing securities with a maturity at the date of purchase of three months or less.

**Income Taxes**

Provisions for income taxes are based on taxes payable or refundable for the current year
and deferred taxes on temporary differences between the amount of taxable income and pretax
financial income and between the tax bases of assets and liabilities and their reported amounts in
the financial statements.  Deferred tax assets and liabilities are included in the financial statement
at currently enacted income tax rates applicable to the period in which the deferred tax assets and
liabilities are expected to be realized or settled as prescribed in FASB Statement No. 109,
Accounting for Income Taxes.  As changes in tax laws or rate are enacted, deferred tax assets and
liabilities are adjusted through the provision for income taxes.

Employees of the corporation are entitled to paid vacations, sick days and other time off
depending on job classification, length of service and other factors.  It is impractical to estimate
the amount of compensation for future absences, and accordingly, no liability has been recorded
in the accompanying financial statements.  The corporation's policy is to recognize the costs of
compensated absences when paid to employees.

**Net earnings per share**

The Company adopted Statement of Financial Accounting Standards No. 128 that
requires the reporting of both basic and diluted earnings per share.  Basic earnings per share is
computed by dividing net income available to common shareowners by the weighted average
number of common shares outstanding for the period.  Diluted earnings per share reflects the
potential dilution that could occur if securities or other contacts to issue common stock were
exercised or converted into common stock.  In accordance with FASB 128, any anti-dilution
effects on net loss per share are excluded.

**Disclosure about fair value of financial instruments**

The Company has financial instruments, none of which are held for trading purposes. The
Company estimates that the fair value of all financial instruments at June 30, 2000 as defined in
FASB 107, does not differ materially from the aggregate carrying values of its financial
instruments recorded in the accompanying balance sheet.  The estimated fair value amounts have
been determined by the Company using available market information and appropriate valuation
methodologies.  Considerable judgment is required in interpreting market data to develop the
estimates of fair value, and accordingly, the estimates are not necessarily indicative of the
amounts that the Company could realize in a current market exchange.

**Fixed assets**

Fixed assets are stated at cost less accumulated depreciation.  Depreciation is recorded on
the following rates, based upon the useful life of the assets.

|Office equipment      | - 20% per annum on the declining balance basis             
|--------------------- | -----------------------------------------------------------
|Leasehold improvement | - allocated on a straight-line basis over the term of lease
|Vehicles              | - 30% per annum on the declining balance basis             
|Computer equipment    | - 30% per annum on the declining balance basis             
|Buildings             | - 4.75% per annum on the straight-line basis               
|Mechanical devices    | - 19% per annum on the straight-line basis                 
|Electric devices      | - 19% per annum on the straight-line basis                 
|Shipping devices      | - 19% per annum on the straight-line basis                 
|Other devices         | - 19% per annum on the straight-line basis                 



**Long-lived assets**

Statement of Financial Accounting Standards No. 121, "Accounting for the Impairment of
Long-Lived Assets and for Long-Lived Assets to be Disposed Of," requires that long-lived assets
be reviewed for impairment whenever events or changes in circumstances indicate that the
carrying amount of the asset in question may not be recoverable.  This standard did not have a
material effect on the Company's results of operations, cash flows or financial position.

**Foreign currency translation**

The functional currency of the parent Company T.Z.F. International Investments, Inc. is the
United States Dollar and of T.Z.F. International Herbs Investment Inc. is the Canadian Dollar and
the reporting currency on a consolidated basis is the United States Dollar.

The assets, liabilities, and operations of the Company are expressed in the functional currency of
the Company in United States Dollars.  Operations of the subsidiary, T.Z.F. International Herbs
Investment Inc. are in Canadian Dollars and in conformity with US GAAP they are translated
into the reporting currency, the United States Dollar.

Monetary assets and liabilities are translated at the current rate of exchange.

The weighted average exchange rate for the period is used to translate revenue, expenses, and
gains or losses from the functional currency to the reporting currency.

The gain or loss on translation is reported as a separate component of stockholders' equity and
not recognized in net income.  Gains or losses on remeasurement are recognized in current net
income.

Gains or losses from foreign currency transactions are recognized in current net income.

Fixed assets are measured at historical exchange rates that existed at the time of the transaction.

Depreciation is remeasured at historical exchange rates that existed at the time the underlying
related asset was acquired.

An analysis of the changes in the cumulative translation adjustment as disclosed as part of
stockholders' equity, is as follows:

|                         | Year ended December 31,
2000 | Year ended December 31,
1999
|------------------------ | ---------------------------- | ----------------------------
|Beginning balance        | $        -                   | $ -                         
|Change during the period | 4,383                        | -                           
|Ending balance           | $ 4,383                      | $ -                         

The effect of exchange rate changes on cash balances is reported in the statement of cash flows
as a separate part of the reconciliation of change in cash and cash equivalents during the period.

**Concentration of credit risk**

Financial instruments that potentially subject the Company to a significant concentration of credit
risk consist primarily of cash and cash equivalents which are not collateralized.  The Company
limits its exposure to credit loss by placing its cash and cash equivalents with high credit quality
financial institutions.

**Inventories**

The inventories are recorded at the lower of cost or market. As at December 31, 2000 the
inventories total $1,244,642

**Revenue Recognition**

The Securities and Exchange Commission (SEC) issued Staff Accounting Bulletin (SAB) 101,
Revenue Recognition in Financial Statements, in December 1999.  The SAB summarizes certain
of the SEC staff's views in applying generally accepted accounting principles to revenue
recognition in financial statements.  During the current year, the Company performed a review of
its revenue recognition policies and determined that it is in compliance with SAB 101.

**Web Site Development Expenses**

Web site development expenses relate to the development of new online services and consist
principally of employee compensation, as well as costs for content, facilities and equipment.  The
consensus in the Financial Accounting Standards Board Emerging Issues Task Force (EITF)
Issue No. 00-2, Accounting for Web Site Development Costs, requires that certain costs to
develop Web sites be capitalized or expensed, depending on the nature of the costs.  During
2000, development expenses of $74,724 have been capitalized and are being amortized over a
period of 30 months.

**Shipping and Handing Fees and Costs**

In September 2000, the Financial Accounting Standards Board Emerging Issues Task Force
(EITF) reached a final consensus on EITF Issue No. 00-10, Accounting for Shipping and
Handling Fees and Costs.  This consensus requires that all amounts billed to a customer in a sale
transaction related to shipping and handling, be classified as revenue.  The Company historically
has netted shipping charges to customers with shipping and handling costs which are included in
operating expenses in the Statements of Operations.  With respect to the classification of costs
related to shipping and handling incurred by the seller, the EITF determined that the
classification of such costs is an accounting policy decision that should be disclosed.  The
Company will adopt the consensus in the Issue in fiscal 2001.

Note 3.  CASH AND CASH EQUIVALENTS - $1,668,711

The total for cash and equivalents as at December 31, 2000, is made up as follows:

|                    | TZF US
Company | The BC
Company | Tian'an  | JZF Jiangsu | Shenzhen
TZF Net | Total       
|------------------- | -------------- | -------------- | -------- | ----------- | ---------------- | ------------
|Petty cash          | $              | $              | $     63 | $    5,625  | $     9,155      | $     14,843
|Cash in trust       | 4,013          | 435            |          |             |                  | 4,448       
|Cash in bank        |                | 57,489         | 179,417  | 999,831     | 407,839          | 1,644,576   
|Short-term deposits |                | 4,844          |          |             |                  | 4,844       
|Total               | $ 4,013        | $62,768        | $179,480 | $1,005,456  | $416,994         | $1,668,711  

Note 4.  ACCOUNTS RECEIVABLE - $5,204,977 (see note 30 re past operations of
subsidiaries)

This balance represents the following:

|                                  | The BC
Company | Tian'an    | JZF Jiangsu | Shenzhen TZF
Net | Total     
|--------------------------------- | -------------- | ---------- | ----------- | ---------------- | ----------
|Accounts receivable,
trade        | $745,511       | $ 348,305  | $1,675,847  | $ 274,132        | $3,043,795
|Accounts receivable,
Canadian GST | 12,881         |            |             |                  | 12,881    
|Short-term loans                  |                | 831,875    | 79,095      | 517,487          | 1,428,457 
|Accounts receivable,
others       | 17,917         |            | 701,927     |                  | 719,844   
|Total                             | $776,309       | $1,180,180 | $2,456,869  | $791,619         | $5,204,977

Note 5.  PREPAID EXPENSES AND DEPOSITS - $34,684

The balance of prepaid expense and deposit as at December 31, 2000, are as follows:

|                     | The BC Company | Tian'an | Shenzhen
TZF  Net | Total  
|-------------------- | -------------- | ------- | ----------------- | -------
|Rental deposits      | $5,384         | $       | $                 | $5,384 
|Prepaid insurance    |                | 1,602   |                   | 1,602  
|Prepaid securities   |                | 1,916   |                   | 1,916  
|Deposit for supplies | 970            | 1,551   | 23,261            | 25,782 
|Total                | $ 6,354        | $ 5,069 | $23,261           | $34,684

Note 6.  SUBSCRIPTIONS RECEIVABLE - $406,434

As at September 11, 2000, Mr. Chung Yiu Chung signed a subscription agreement with the
Company, whereby he subscribed for 561,798 common share of the Company at a price of
CAD$1.50 per share, of which, 162,994 common shares were issued and paid.  The balance of
$406,434 is unpaid and is disclosed as a current asset in these financial statements.



Note 7.  INVENTORIES - $1,244,642

The inventories as at December 31, 2000, are made up as follows:

|                    | The BC
Company | Tian'an   | TZF Jiangsu | Shenzhen
TZF Net | Total     
|------------------- | -------------- | --------- | ----------- | ---------------- | ----------
|Raw materials       | $              | $ 72,367  | $ 61,422    | $                | $133,789  
|Packaging materials | 22,947         | 14,350    | 541,738     |                  | 579,035   
|Finished products   |                | 261,485   | 121,681     |                  | 383,166   
|Other               |                |           | 136,619     | 12,033           | 148,652   
|Total               | $   22,947     | $ 348,202 | $ 861,460   | $ 12,033         | $1,244,642

Note 8.  INVESTMENT IN GUANGDONG HONGKANG MEDICAL COMPANY

As at December 31, 2000, Shenzhen TZF Net had advanced $532,044 to Guangdon Hongkang
Medical Company for that company to establish a new marketing network.  It is proposed that the
aforementioned company will acquire the operations of and ownership of Meixian Hengkang
Pharmaceutical Company in 2001.

Note 9.  FIXED ASSETS

The totals for fixed assets and accumulated depreciation as at December 31, 2000, are made up
as follows:

|                             | The BC
Company | Tian'an    | TZF
Jiangsu | Shenzhen
TZF Net | Total     
|---------------------------- | -------------- | ---------- | ----------- | ---------------- | ----------
|**Cost**                     |                |            |             |                  |           
|Computer equipment           | $ 14,364       | $          | $           | $                | $14,364   
|Office equipment             | 14,286         |            |             |                  | 14,286    
|Vehicles                     | 19,025         |            |             |                  | 19,025    
|Buildings and
improvement    | 38,426         | 1,312,794  | 285,913     | 36,276           | 1,673,409 
|Mechanic devices             |                | 321,187    | 198,027     |                  | 519,214   
|Shipping devices             |                | 21,685     | 144,649     |                  | 166,334   
|Electronic devices           |                |            | 35,579      | 45,591           | 81,170    
|Other                        |                | 313,581    | 60,348      |                  | 373,929   
|Total                        | 86,101         | 1,969,247  | 724,516     | 81,867           | 2,861,731 
|**Accumulated
Depreciation** |                |            |             |                  |           
|Computer equipment           | 1,645          |            |             |                  | 1,645     
|Office equipment             | 2,593          |            |             |                  | 2,593     
|Vehicles                     | 1,896          |            |             |                  | 1,896     
|Buildings                    | 7,457          | 246,169    | 52,010      | 2,914            | 308,550   
|Mechanic devices             |                | 113,948    | 44,786      |                  | 158,734   
|Shipping devices             |                | 19,517     | 33,730      |                  | 53,247    
|Electronic devices           |                |            | 13,260      | 760              | 14,020    
|Other                        |                | 183,762    | 32,309      |                  | 216,071   
|Total                        | 13,591         | 563,396    | 176,095     | 3,674            | 756,756   
|**Net book value**           |                |            |             |                  |           
|Computer equipment           | 12,719         | 0          | 0           | 0                | 12,719    
|Office equipment             | 11,693         | 0          | 0           | 0                | 11,693    
|Vehicles                     | 17,129         | 0          | 0           | 0                | 17,219    
|Buildings                    | 30,969         | 1,066,625  | 233,903     | 33,362           | 1,364,859 
|Mechanic devices             | 0              | 207,239    | 153,241     | 0                | 360,480   
|Shipping devices             | 0              | 2,168      | 110,919     | 0                | 113,087   
|Electronic devices           | 0              | 0          | 22,319      | 44,831           | 67,150    
|Other                        | 0              | 129,819    | 28,039      | 0                | 157,858   
|Total                        | $    72,510    | $1,405,851 | $ 548,421   | $ 78,193         | $2,104,975

Note 10. FIXED ASSETS - OTHERS

As at December 31, 2000, other fixed assets of $239,261 represents the residual value of fixed
assets located at TZF Jiangsu.

Note 11.   FIXED ASSETS - CONSTRUCTION IN PROGRESS

The construction in progress of $1,918,374 as at December 31, 2000, applies to new buildings
and related equipment located at TZF Jiangsu and will not be depreciated until the building has
been completed and the equipment put into use during 2001.  The additional cost to complete  is
approximately $2,653,204, see note 27, contractual commitments.

Note 12. GOODWILL

As at December 31, 2000, goodwill of $1,206,554 is made up as follows:

|                         | Tian'an  | TZF Jiangsu | Shenzhen TZF  Net | Total     
|------------------------ | -------- | ----------- | ----------------- | ----------
|Goodwill on acquisitions | $147,177 | $           | $1,059,377        | $1,206,554

The goodwill will be amortized over a twenty year period and will be evaluated on an annual
basis as to any possible impairment.

Note 13. INTANGIBLE ASSETS - DEFERRED COSTS

As at December 31, 2000, deferred costs of $102,681 are made up as follows:

|                                                       | Tian'an  | Shenzhen
TZF  Net | Total   
|------------------------------------------------------ | -------- | ----------------- | --------
|Website development - to be amortized over 30 months   |          | $ 74,724          | $74,724 
|Net product development costs - to be expensed in 2001 | $ 27,957 |                   | $ 27,957
|Total                                                  | $ 27,957 | $ 74,724          | $102,681

Note 14.  INTANGIBLE ASSETS - TECHNOLOGY RIGHTS

By agreement dated December 15, 1999, Shenzhen Hengyunda Enterprises Co. Ltd. of P.R.
China agreed to sell and assign certain information and rights relating to a series of products
known as the Snow Lotus Tea series products to the BC Company.

The BC Company agreed to pay consideration of $4,038,229 for acquisition of these assets,
through the issuance of 6,000,000 shares of its Class B common stock, which were valued for
purposes of the acquisition at a price of CAD$1.00 per share, for total consideration of
CAD$6,000,000 (US$4,038,229).

Shenzhen Hengyunda Enterprises Co. Ltd. has warranted that there are no charges or
encumbrances against the rights being acquired.

This agreement includes the sale, assignment and transfer of all the right, title and interest in and
to the Product Information and all the rights to use, exploit, develop or otherwise deal with the
Product Information or the Project, including the right to register any Intellectual Property in
connection with the Product, the same to be held and enjoyed by the BC Company and its
successors and assigns as fully and effectively as the same would have been held and enjoyed by
Shenzhen Hengyunda Enterprises Co. Ltd. had this transfer and assignment not been made.

Shenzhen Hengyunda Enterprises Co. Ltd. further agrees to execute and deliver all such
documents and further assurances as may be necessary or desirable to give effect to the sale and
assignment.

Amortization of the cost of the technology will commence when the products relating to the
technologies are available to be marketed; which is expected to be effective January 1, 2001.
The amortization period is for ten years on a straight-line basis.

Note 15.  ACCOUNTS PAYABLE AND ACCRUED

Details of the total of accounts payable and accrued as at December 31, 2000, are as follows:

|                      | TZF  US
Company | The BC
Company | Tian'an  | Second
Pharmacy | Shenzhen
TZF Net | Total     
|--------------------- | --------------- | -------------- | -------- | --------------- | ---------------- | ----------
|A/R, trade            | $               | $ 60,819       | $ 9,921  | $913,669        | $ 6,829          | $ 991,238 
|Accrued payroll
taxes |                 | 59,228         | 0        | 94,821          |                  | 154,049   
|Taxes payable         |                 |                | 50,264   | 389,934         | 151,804          | 592,002   
|Other payables        | 923             | 45,228         | 42,176   | 350,001         | 574,813          | 1,013,141 
|Total                 | $    923        | $165,275       | $102,361 | $1,748,425      | $ 733,446        | $2,750,430

Note 16.  MANAGEMENT FEES PAYABLE - $150,004

Detail of the total of management fees payable as at December 31, 2000, are as follows:

|Mr. Xin Chen | $ 71,195
|------------ | --------
|Mr. Chung Yu | $ 54,032
|Mr. Eric Liu | $ 24,777
|TOTAL        | $150,004



Note 17.  RELATED PARTY TRANSACTIONS

a) By a director resolution, each of Mr. Eric Liu, Director and Vice-president of the Company,
Mr. Chung Yu, Director and CEO of the Company and Mr. Xin Chen, Director and Chairman of
the Company will be paid CAD$8,000 per month as remuneration, effective December 1, 1998.
Payment of such director's fees may be deferred until such time as the Company has had a public
offering, or as the Board of Directors otherwise decides in view of the financial situation of the
Company.

As at December 31, 2000, management fees payable for which payment was deferred total
$150,004 (see note 16).

b) The amount of $515,053 is due to related parties as at December 31, 2000. This amount is
unsecured, non interest bearing, with no specific terms of repayment.  Details are as follows:

|Mr. Xin Chen | $499,776
|------------ | --------
|Mr. Chung Yu | $ 15,277
|Total        | $515,053

c) The principal shareholders offered to all warrant holders to exchange their warrants for shares
held by the principal shareholders pursuant to such ratio so that, with the completion of the
warrant/share exchange, the per share cost of the share/warrant held by the minority shareholder
effectively stands at CAD$0.75 per share.  The share/warrant change became effective as of
December 17, 2000.

d) During the fiscal year ending December 31, 2000, Mr. Xin Chen, Director and Chairman of
Board of Directors of the Company, advanced a total of approximately $5,500,000 on behalf of
the Company. These funds were used in part for purchase of the assets of TZF Jiangsu, and in
part for purchase of all of the issued and outstanding stock of Tian'an Investments Limited, a
British Virgin Islands Corporation (which was completed on December 21, 2000) and part of the
payment on the acquisition of 100% issued and outstanding shares of Shenzhen T.Z.F. Network
Technologies Co., Ltd.

On December 28, 2000, the Company signed a Debt Settlement Agreement with Mr. Xin Chen.
Mr. Chen agreed to take 10,000,000 common shares of the Company at a price of CAD$0.75
(US$0.50) per share to repay $5,000,000 of his loan.  The 10,000,000 shares also have
10,000,000 warrants attached entitling the holder to purchase additional 10,000,000 common
shares of the Company at a price of CAD$1.50 per share until December 28, 2001 and thereafter
at a price of CAD$2.50 per share until December 28, 2002.

Note 18.  BANK LOANS

Details of the total of bank loans as at December 31, 2000, are as follows:

a) Tian'an

As at October 20, 2000, Tianan obtained a one year term loan of RMB4,000,000 (equivalent to
US$483,676) from Bank of China Xiamen Branch at an interest rate of 6.435% per annum
payment monthly.  This loan is secured by the assets of Tianan.

b) TZF Jiangsu

As at December 31, 2000, TZF Jiangsu has bank loans, as follows:

|                                              | Period of Loan     | Principal

Chinese
RMB | Principal

Equivalent to US $ | Interest
Rate/Monthly
|--------------------------------------------- | ------------------ | ---------------------- | ----------------------------- | ---------------------
|Industries and
Commerce Bank of
Jianhu, China |                    |                        |                               |                      
|                                              | 5/17/00 - 3/5/01   | $800,000               | $ 96,736                      | 0.63315%             
|                                              | 7/25/00 - 5/5/01   | $2,528,000             | 305,683                       | 0.63315%             
|                                              | 8/28/00 - 6/5/01   | 1,750,000              | 211,608                       | 0.63315%             
|                                              | 9/5/00 - 7/5/01    | 1,600,000              | 193,470                       | 0.63315%             
|                                              | 11/25/00 - 9/5/01  | 1,882,00               | 227,570                       | 0.63315%             
|China Construction
Bank                       |                    |                        |                               |                      
|                                              | 12/29/00 - 7/17/01 | 500,000                | 60,459                        | 0.685%               
|Total                                         |                    | $9,060,000             | $1,095,526                    |                      

These loans are secured by the assets of TZF Jiangsu.

c) Summary of Bank loans

|                                      | Tian'an  | TZF Jiangsu | Total     
|------------------------------------- | -------- | ----------- | ----------
|Bank of China Xiamen Branch           | $483,676 | $           | $483,676  
|Industries and Commerce Bank of China |          | 1,035,067   | 1,035,067 
|China Construction Bank               |          | 60,459      | 60,459    
|Total                                 | $483,676 | $1,095,526  | $1,579,202

Note 19.  LONG-TERM LIABILITIES

a) The long-term debt of $306,138 represents long-term accounts payable owing by Second
Pharmacy

b) The deferred liabilities for pensions applies to Tianan.  This is a provision for pension
liabilities.

Note 20.  CAPITAL STOCK

a) Authorized:  100,000,000 common shares with a par value of $0.0001 each per share.

b) Issued and outstanding common shares as at December 31, 2000 are as follows:

|                                  | Issue
Date | Number of
Shares | Par
Value | Additional
Paid-in
Capital | Total      
|--------------------------------- | ---------- | ---------------- | --------- | -------------------------- | -----------
|Private placement                 | 9/25/98    | 1,000,000        | $1,000    | $1,500                     | $2,500     
|**Balance**                       | 12/31/98   | 1,000,000        | 1,000     | 1,500                      | 2,500      
|Private placement                 | 2/17/99    | 600,000          | 600       | 59,400                     | 60,000     
|**Balance**                       | 12/31/99   | 1,600,000        | 1,600     | 60,900                     | 62,500     
|Cancellation of common
stock      | 4/30/00    | (1,000,000)      | (1,000)   | 1,000                      |            
|**Balance, before forward
split** | 4/30/00    | 600,000          | $600      | $61,900                    | $62,500    
|10:1 forward split                | 5/15/00    | 6,000,000        | 600       | 61,900                     | 62,500     
|Issuance of stock for
services    | 5/15/00    | 250,000          | 25        | 252,375                    | 252,400    
|Acquisition of the BC
Company     | 5/15/00    | 18,451,843       | 1,845     | 5,351,087                  | 5,352,932  
|Issuance for cash                 | 7/4/00     | 340,000          | 34        | 343,216                    | 343,250    
|Issuance for cash                 | 9/30/00    | 615,466          | 62        | 621,286                    | 621,348    
|Issuance for cash                 | 10/19/00   | 10,000           | 1         | 10,999                     | 11,000     
|Issuance for cash                 | 11/19/00   | 230,000          | 23        | 252,977                    | 253,000    
|Issuance for debt                 | 12/28/00   | 10,000,000       | 1,000     | 4,999,000                  | 5,000,000  
|Negative goodwill                 | 12/31/00   |                  |           | 3,333,103                  | 3,333,103  
|**Balance**                       | 12/31/00   | 35,897,309       | $3,590    | $15,225,943                | $15,229,533

c) Outstanding Warrants at December 31, 2000

537,000 warrants to purchase 537,000 common shares exercisable at CAD$2.00 per share until
December 17, 2001



2,231,311 warrants to purchase 2,231,311 common shares exercisable at CAD$2.50 per share
until December 17, 2001



10,000,000 warrants to purchase 10,000,000 common shares exercisable at CAD$1.50 per shares
until December 28, 2001, and thereafter exercisable at CAD$2.50 per share until December
28,2002.

Note 21.  INCOME TAXES

a) The most recent Federal Income Tax filing for the Company for the US was for the year ended
December 31, 1999, disclosing no income taxes payable to the US Internal Revenue Service.



b) The BC Company has not filed any Federal Income Tax Returns since its incorporation on
May 15, 1998 and will be filing 1999 and 2000 Income Tax Returns in the first quarter of 2001.
To December 31, 1999, the BC Company had a total loss of CAD$482,634 (equivalent to
US$321,756).  No provision for Canadian Income Taxes is provided for in these consolidated
financial statements as the profit is reduced by other costs of the Company.

Note 22.  FINANCIAL INSTRUMENTS

The Company's financial instruments consist of cash and cash equivalents, accounts receivable,
prepaid expenses and deposits, subscriptions receivable, short-term investment, inventories,
accounts payable and accrued, management fees payable, balances due to related parties, payable
on acquisition and long-term liabilities.  It is management's opinion that the Company is not
exposed to significant interest, currency or credit risks arising from these financial instruments.
The fair value of these financial statements approximated their carrying values.

Note 23.  LEASE OBLIGATIONS



a)  Canon Copier (NP-3825) Lease

On October 1, 1999, the Company entered into a 48 month lease with Dominion Technologies
for a Canon Copier to be used by the Company.  Lease payments are expensed as they are
incurred.  Lease obligations are as follows:

|2001 | CAD$	1,327
|---- | ----------
|2002 | CAD$	1,327
|2003 | CAD$	995  

b)  Computer Lease

On October 1, 1999, the Company entered into a 36 month lease with Dominion Technologies
for computer equipment to be used by the Company.  Lease payments are expensed as they are
incurred.  Lease obligations are as follows:



|2001 | CAD$	2,947
|---- | ----------
|2002 | CAD$	2,210

c)	Vehicles Lease

On July 29, 1999, the Company entered into a 36 month lease with Mercedes-Benz Credit of
Canada Inc. for two vehicles to be used by the Company.  Lease payments are expensed as they
are incurred.  Lease obligations are as follows:

|2001 | CAD$	20,927
|---- | -----------
|2002 | CAD$	12,207



d)	Lease of Premises

The Company entered into a lease for offices on April 26, 1999 with Omnia Overseas
Trading Ltd. for three years for monthly rent and costs of CAD$3,133.51, commenced on July 1,
1999.



The first and the last months rent of  CAD$6,631.15 is due at the time of signing.  This
amount has been paid and is recorded as prepaid expense and deposit as at December 31, 2000.

Summary of lease obligations

|Year | CDN$    | Equivalent US$
|---- | ------- | --------------
|2001 | $62,803 | $42,269       
|2002 | $34,545 | $23,250       
|2003 | 995     | 670           
|     | $98,343 | $66,189       

Note 24.  PENSION AND EMPLOYMENT LIABILITIES

The Company has liabilities which was deferred as at December 31, 2000, for pension, post-employment benefits or post-retirement benefits in Tianan in the amount of $212,562.  The
parent company and other subsidiary companies, (except for Tianan) do not have any liabilities
for pensions and related costs.

Note 25.  DISTRIBUTORSHIP AGREEMENTS

The Company enters into various distributorship agreements with independent third parties to
market products of the Company and its subsidiaries.

Note 26.  LAWSUITS

a)	Expediter Sales Ltd. ("Expediter") v. the BC Company

This a claim against the BC Company alleging a breach of contract and misrepresentation.
Expediter is seeking damages for alleged loss of profits, loss of business and goodwill,
misrepresentation, set-up expenses and the alleged wrongful use of Expediter's name.  Further,
Expediter is seeking an injunction to prevent the BC Company from selling and herbal tea in
Canada.  The BC Company terminated the contract for non performance and has counterclaimed
against Expediter for outstanding debts.

b)	Lily Hong Qian and the Company

Ms. Lily Hong Qian has complained about her investment in the BC Company.  She has
threatened to commence an action against the Company and others, however, no action was
commenced as at December 31, 2000.

Note 27.  CONTRACTUAL COMMITMENTS

A subsidiary, TZF Jiangsu has contractual obligations totalling $2,653,204 to builders, suppliers
and subtrades relating to construction in progress of buildings and equipment as of December 31,
2000.

Note 28.  SALES IN CANADA

The Company maintains a products analysis and quality control system for its products to be
distributed in order to ensure that its products conform to relevant regulatory requirements
including health requirements.  Where any products are found not to meet the regulatory
requirements, the Company will immediately take such measures as necessary, or cause such
measures to be taken, so that the said regulatory requirements are complied with.

Note 29.  SHORT-TERM INVESTMENT

As at December 31, 2000, Shenzhen TZF Net invested $1,354,293 in Shenzhen Shengqi
Investments Ltd. for a one year term (October 12, 2000 to October 12, 2001).  This investment is
secured by the assets of Shenzhen Shengqi Investments Ltd. and guaranteed at least 12% return
per annum.

Note 30.  REVENUES OF ACQUISITIONS

During the year, the Company acquired four companies and the consolidated operations,
recorded as a purchase, are required by the parent to only disclose operating figures for these
acquisitions from the date of acquisition.  Details of the operating figures for all the companies
for twelve month period ended December 31, 2000 extracted from the applicable audited
financial statements of these companies, are as follows:

|                           | TZF US
Company | The BC
Company | Tian'an    | TZF
Jiangsu | Shenzhen
TZF Net | Total     
|-------------------------- | -------------- | -------------- | ---------- | ----------- | ---------------- | ----------
|Revenue                    |                |                |            |             |                  |           
|Sales                      | $              | $1,633,897     | $1,251,866 | $3,637,046  | $1,347,541       | $7,870,350
|Cost of sales              |                | 706,214        | 630,706    | 2,518,320   | 984,843          | 4,840,083 
|Gross profit               |                | 927,683        | 621,160    | 1,118,726   | 362,698          | 3,030,267 
|Selling
expenses           |                | 53,609         | 73,835     | 300,400     | 34,509           | 462,353   
|                           |                | 874,074        | 547,325    | 818,326     | 328,189          | 2,567,914 
|Other income               | 923            | 226,117        | 15,240     | 1,101,753   | 314,148          | 1,658,181 
|                           | 923            | 1,100,191      | 562,565    | 1,920,079   | 642,337          | 4,226,095 
|Administrative
costs       | 49,485         | 488,311        | 203,513    | 470,199     | 33,174           | 1,244,682 
|Stock-based
compensation   | 252,400        |                |            |             |                  | 252,400   
|Other expenses             |                | 5,296          | 11         | 42,761      | 60               | 48,128    
|                           | 301,885        | 493,607        | 203,524    | 512,960     | 33,234           | 1,545,210 
|Profit (loss)
before taxes | (300,962)      | 606,584        | 359,041    | 1,407,119   | 609,103          | 2,680,885 
|Income taxes               |                |                | 53,858     | 13,500      | 119,419          | 186,777   
|**Net profit
(loss)**      | $(300,962)     | $606,584       | $305,183   | $1,393,619  | $489,684         | $2,494,108

Note 31.  SUBSEQUENT EVENTS

By agreement dated December 15, 2000, effective January 1, 2001, Trophic Canada Ltd. ("the
Supplier"), granted TZF International Investments, Inc. (TZF) the exclusive right to promote,
distribute, and sell the supplier's products within the "Territory" of China, which includes Hong
Kong, SAR, for a period of five years.  Continuation of this exclusive right is continent upon
meeting or exceeding the purchase of products for a minimum of CAD$50,000 within the first
distribution year, a minimum of CAD$200,000 within the second distribution year, and increases
of approximately 20% in each of the subsequent distribution years.

The supplier may terminate the distribution agreement if TZF breaches any terms of the
agreement, including but not restricted to the annual sales requirements, if any breaches are not
remedied within three months after written notice.

TZF cannot assign the agreement or subcontract its obligations under the agreement without the
consent in writing of the supplier.  The supplier is an arms length party unrelated to TZF.

ITEM 8.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE.

On May 1, 2000, the Company appointed Moen & Company, Chartered Accountants,
1400 IBM Tower, 701 West Georgia Street, Vancouver, B.C. as their independent auditor. Prior
to Moen & Company, the Company had engaged Parker & Co., Chartered Accountants, as their
independent auditor.



ITEM 9.	DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL
PERSONS; COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT.

The directors and executive officers currently serving the Company are as follows:

|Name             | Age | Tenure                                            
|---------------- | --- | --------------------------------------------------
|Xin Chen         | 37  | Chairman and a Director since February 1999       
|Chung Yu         | 40  | CEO, President, and a Director since February 1999
|Qing Liu         | 45  | Vice President and a Director since February 1999 
|Robert L. Hallam | 55  | Director since February 2000                      
|Hong Li          | 39  | Director since February 2000                      
|Chun Sheng Guo   | 35  | Director since February 2000                      



The directors named above will serve until the next annual meeting of the Company's
stockholders.  Thereafter, directors will be elected for one-year terms at the annual stockholders'
meeting.  Officers will hold their positions at the pleasure of the board of directors, absent any
employment agreement, of which none currently exists or is contemplated.  There is no
arrangement, plan or understanding between any of the directors or officers of the Company and
any other person pursuant to which any director or officer was or is to be selected as a director or
officer, and there is no arrangement, plan or understanding as to whether non-management
shareholders will exercise their voting rights to continue to elect the current directors to the
Company's board.  There are also no arrangements, agreements or understandings between
non-management shareholders and management under which non-management shareholders may
directly or indirectly participate in or influence the management of the Company's affairs.

Biographical Information of Directors and Executive Officers follows:

Xin Chen

Mr. Chen is the founder and Chairman of the board of directors of the Company.
Presently, Mr. Chen is also the Chairman, President and CEO of Xin Hai Group and the
Chairman of its subsidiaries Ningbo Success Information Industry Co Ltd. and Shanghai New
Star Real Estate Development Co., Ltd.  Ningbo Success Information Industry Co., Ltd., is listed
on the Shen Zhen Stock Exchange in China   Mr. Chen is also the honorary Dean of the Finance
Faculty and visiting professor at JiangXi Finance University and a visiting professor at the
Beijing Commerce University.  Mr. Chen is also Chairman of the board of directors of the.

Chung Yu.



Mr. Chung Yu is President and CEO of the Company, as well as a director.  Mr. Chung
Yu is the honorary president of the Canadian Chinese Herbal Professional & Merchants
Association, Vice-Chairman of the Canadian Chinese Chamber of Commerce, and a member of
the Chinese Entrepreneurial Society of Canada.  Mr. Chung Yu was the former director and vice-president of Hong Kong KunZe Enterprise Ltd., president of China Hua Pu Group, and a director
of RoRo International Trading, Ltd.  With over 12 years as the president of China Hua Pu Group,
Mr. Yu will contribute his expertise to the startup and management of the Company.

Qing Liu.

Mr. Liu is the Vice President for North America & Asia and is Vice President and a
director of the Company. From 1995 to 1999, Mr. Liu was the Chairman and President of Beijing
T.Z.F. Commerce and Trade Group, Chairman of the Board of Directors of Beijing YoungHeng
Advertising Company, President of Beijing Kai Huan medicine manufacturing company, and the
President of Beijing Zhong Jia Yi Medical and Pharmaceutical Technology Development
Company.  Mr. Liu is the honorary Chairman of the S.T.A.U.N.C.H. (The Society for
Therapeutic Alternatives Using Natural Chinese Healing Methods) Foundation in Canada and a
committee member of the Chinese Business Association of Canada.

Robert L. Hallam.

Mr. Hallam is a director of the Company.  He was the President and Director of Robert L.
Hallam Environmental Management, Ltd., Director of Knight Piesold, Ltd., and President,
Director and CEO of Hallam Knight Piesold, Ltd.  Mr. Hallam recently became Director of Tai
Li Environment Engineering, Ltd., a firm based in Kumming, Yunnan, China.  In 1995, Mr.
Hallam established a new company, Oriental Express Trading Corporation, of which he is a
Director and 50% owner.  This new company has been involved in the export of Canadian
products, primarily telecommunications equipment, to the People's Republic of China and the
importing of Chinese herbal medicines for the treatment of AIDS patients.

Hong Li.

Mr. Li is a director of the Company, and is involved with introducing investors from
Asia.  Mr. Li was the Secretary of the Board of Directors of Shenzhen Tianyuan Industry, Inc.,
and was responsible for raising capital.  Mr. Li was also the Vice President of Hainan HengTai
Group, Ltd, a Shanghai Stock Exchange company.  Presently, Mr. Li is the director of ShenZhen
Xinhai Industrial & Trading, Ltd., and is a director and CEO of Ningbo Success Information
Industry Co. Ltd.

Chung Sheng Guo.

Mr. Guo is a director of the Company.  Since 1994, he has worked for ShenZhen Xinhai
Industrial & Trading, Ltd. as the manager.  In this capacity, he specialized in import and export,
and projects for overseas investment.  Mr. Guo will be responsible for China-based production.

Compliance with Section 16(a) of the Exchange Act

The Company's officers, directors and principal shareholders have each filed an Initial Statement
of Beneficial Ownership of Securities on Form 3.

ITEM 10.	EXECUTIVE COMPENSATION.

By directors' resolution dated December 1, 1998, the Company agreed to pay each of Mr.
Chung Yu, Mr. Xin Chen, and Mr. Qing (Eric) Liu a management fee of CAD $8,000
(approximately $5,384 U.S. dollars) per month effective as of the date of the resolution.  The
resolution also authorized the Company to defer payment all, or a portion, of such management
fees until such time as the Company has had a public offering, or as the Board of Directors
decides in view of the Company's financial resources.

During the fiscal year ending December 31, 2000, the Company paid each of the named
directors and officers a total of CAD $72,000 (approximately $48,456 U.S.), and deferred a total
of CAD $24,000 (approximately $16,152 U.S.).

As at December 31, 2000, the accrued but unpaid portion of the management fees due to each of
the named officers and directors was as follows:

|              | Xin Chen | Chung Yu | Eric Liu | Total   
|------------- | -------- | -------- | -------- | --------
|Amount unpaid | $71,195  | $54,032  | $24,777  | $150,004

****ITEM 11.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT.  		****

The following table sets forth, as of December 31, 2000, the stock ownership of each
executive officer and director of T.Z.F. International Investments, Inc., of all executive officers
and directors as a group, and of each person known by T.Z.F. International Investments, Inc. to
be a beneficial owner of 5% or more of its Common Stock.  Except as otherwise noted, each
person listed below is the sole beneficial owner of the shares and has sole investment and voting
power as such shares.  No person listed below has any options, warrants or other rights to acquire
additional securities of T.Z.F. International Investments, Inc., except as may be otherwise noted.

|Name and Address                                                           | Number of Shares
Owned Beneficially | % of Class Owned
|-------------------------------------------------------------------------- | ----------------------------------- | ----------------
|Xin Chen (1)

3381 Fleming Street

Vancouver, B.C. V5N 3V6                 | 14,647,308                          | 40.80%          
|Chung Yu (1)

3381 Fleming Street

Vancouver, B.C. V5N 3V6                 | 1,429,941                           | 3.98%           
|Qing Liu (1)

#308 - 8625 Logan Street

Vancouver, B.C. V6P 3T3            | 1,072,456                           | 2.99%           
|Robert L. Hallam (1)

5501 Nancy Greene Way

North Vancouver, B.C. V7R 4R6 | 0                                   | 0%              
|Hong Li (1)

3381 Fleming Street

Vancouver, B.C. V5N 3V6                  | 20,000                              | 0.06%           
|Chun Sheng Guo (1)

3381 Fleming Street

Vancouver, B.C. V5N 3V6           | 0                                   | 0%              
|Shenzhen Hengyunda Enterprises

Co. Ltd.

Shenzhen, China                  | 6,000,000                           | 16.71%          
|All directors and executive officers (6 persons)                           | 17,169,705                          | 47.83%          

(1)  The person listed is an officer, a director, or both, of the Company.

ITEM 12.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

As of December 31, 2000, the Company had outstanding loans from related parties
totaling $515,053, including $499,776 owed to Mr. Xin Chen and $15,277 owed to Mr. Chung
Yu.  These amounts are unsecured, non-interest bearing obligations, with no specific terms of
repayment.

Three of the Company's principal shareholders offered certain warrant holders of the
Company the opportunity to exchange all, or a portion, of their warrants for shares of common
stock then held by such principal shareholders.  The warrant holders to which the offer was made
had acquired their warrants through purchase of units consisting of one share of common stock
and one warrant. The warrants allow the holder to purchase one share of common stock of the
Company at a price of CAD $1.50 per share (approximately $1.00 U.S.) if exercised on or before
December 17, 2000, and at a price of CAD $2.50 per share (approximately $1.675 U.S.) if
exercised after December 17, 2000 and on or before December 17, 2001.  A portion of the units
were offered and sold by the Company at a price of CAD $1.00 (approximately $ 0.67 U.S.) and
a portion were offered and sold by the Company at a price of CAD $1.50 (approximately $1.00
U.S.).  The purpose of the exchange offer was to reduce the effective per share price paid by each
of the warrant holders for purchase of shares of the Company to CAD $0.75 (approximately
$0.50 U.S.).



The exchange was completed on December 17, 2000, and on that date, the three principal
shareholders exchanged a total of 2,850,295 of their shares of common stock of the Company
(including 452,692 shares exchanged by Mr. Xin Chen, 1,020,059 shares exchanged by Mr.
Chung Yu and 1,377,544 shares exchanged by Mr. Eric Liu) to acquire 100% of the warrants
which had been offered and sold as part of the CAD $1.00 units and 33% of the of the warrants
which had been offered and sold as part of the CAD $1.50 units.

During the fiscal year ending December 31, 2000, Mr. Xin Chen, Director and Chairman
of the Board of the Company, advanced a total of approximately $5,500,000 on the behalf of the
Company.  These funds were used in part for purchase of the assets of T.Z.F International Herbs
(Jiangsu), Co, Ltd., in part for purchase of all of the issued and outstanding stock of Tian'an
Investments Limited, a British Virgin Islands Corporation, and in part for the purchase of 100%
of the issued and outstanding stock of Shenzhen Tianzifu Network Technologies Co., Ltd.

On December 28, 2000, the Company signed a Debt Settlement Agreement with Mr. Xin
Chen.  Mr. Chen agreed to accept a total of 10,000,000 shares of common stock of the Company
and 10,000,000 warrants in payment of $5,000,000 of his loan.  For purposes of this transaction,
the 10,000,000 shares were valued at a price per share of CAD $0.75 (approximately $ 0.50
U.S.), Each of the 10,000,000 warrants entitles the holder thereof to purchase one share of
common stock of the Company at a price of CAD $1.50 (approximately $1.00 U.S.) if exercised
on or before December 28, 2001, and at a price of CAD $2.50 (approximately $1.675 U.S.) if
exercised after December 28, 2001 and on or before December 31, 2002.

ITEM 13.	EXHIBITS AND REPORTS ON FORM 8-K.

(a)  The Exhibits listed below are filed as part of this Annual Report.



Exhibit No.				Document

2.1		Agreement for Share Exchange (incorporated by reference from Registration
Statement on Form 10-SB filed with the Securities and Exchange Commission on
August 21,  2000).

2.2		Stock Purchase Agreement (incorporated by reference from Registration
Statement on Form 10-SB filed with the Securities and Exchange Commission on
August 21,  2000).

3.1		Articles of Incorporation (incorporated by reference from Registration Statement
on Form 10-SB filed with the Securities and Exchange Commission on August
21,  2000).

3.1a		Amendment to Articles of Incorporation (incorporated by reference from
Registration Statement on Form 10-SB filed with the Securities and Exchange
Commission on August 21,  2000).

3.2		Bylaws (incorporated by reference from Registration Statement on Form 10-SB
filed with the Securities and Exchange Commission on August 21,  2000).

4.1		Specimen Common Stock Certificate (incorporated by reference from
Registration Statement on Form 10-SB filed with the Securities and Exchange
Commission on August 21,  2000).



(b) No reports on Form 8-K were filed by the Company during the last quarter of its fiscal
year ending December 31, 2000.  However, in the first quarter of the fiscal year ending December
31, 2001, the Company filed 3 reports on Form 8-K to report events which occurred during the
last quarter of the fiscal year ending December 31, 2001.   The 8-K reports filed during the first
quarter of the fiscal year ending December 31, 2001, were as follows:

- Report on Form 8-K dated December 21, 2000, to report the acquisition ofall of the
issued and outstanding capital stock of Tian'an Investments Limited, a British Virgin
Islands corporation.  The sole asset of Tian'an Investments Limited is100% ownership of
Tian'an Pharmacy (Xiamen) Co.,  Ltd.The initial report on Form 8-K did not contain
financial statements.  On or about March 26, 2001, the Company filed an amended report
on Form 8-K which included financial statements of Tian'an Pharmacy (Xiamen) Co,
Ltd., as well as pro forma consolidated financial statements.
- Report on Form 8-K dated December 31, 2000, to report the acquisition ofall of the
assets of Second Pharmacy Factory of Yancheng City, ("Second Pharmacy"), a Chinese
corporation, and to report the issuance of 10,000,000 shares to Mr. Xin Chen in payment
of his outstanding loan to the Company.The initial report on Form 8-K did not contain
financial statements.  On or about March 26, 2001, the Company filed an amended report
on Form 8-K which included financial statements of T.Z.F. International Herbs (Jiangsu)
Co., Ltd., (previously known as Second Pharmacy), as well as pro forma consolidated
financial statements.
- Report on Form 8-K dated December 31, 2000, to report thepurchase of all the issued
and outstanding common stock of Shenzhen Tianzifu Network Technology Ltd,
("Shenzhen Tianzifu"), a Chinese corporation.  The report on Form 8-K included
financial statements ofShenzhen Tianzifu Network Technology Ltd,as well as pro forma
consolidated financial statements.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**T.Z.F. INTERNATIONAL INVESTMENTS, INC.**

By:/S/ CHUNG YU

Chung Yu, President, Chief Executive Officer, and a Director

By: /S/ XIN CHEN

Xin Chen, Chairman of the Board

By: /S/ HONG LI

Hong Li, a Director

By: /S/ ROBERT S. HALLAM

Robert S. Hallam, a Director

By: /S/ CHUN SHENG GUO

Chun Sheng Guo, a Director

By: /S/ QING LIU

Qing Liu, Vice President and a Director

Date:	April 13, 2001